Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 96
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A MT-TL1 variant identified by whole exome sequencing in an individual with intellectual disability, epilepsy, and spastic tetraparesis

  • de Boer, Elke
  • Ockeloen, Charlotte W.
  • Matalonga, Leslie
  • Horvath, Rita
  • Solve-RD SNV-indel working group
  • Rodenburg, Richard J.
  • Coenen, Marieke J.H.
  • Janssen, Mirian
  • Henssen, Dylan
  • Gilissen, Christian
  • Steyaert, Wouter
  • Paramonov, Ida
  • Solve-RD-DITF-ITHACA
  • Trimouille, Aurélien
  • Kleefstra, Tjitske
  • Verloes, Alain
  • Vissers, Lisenka E.L.M.
The genetic etiology of intellectual disability remains elusive in almost half of all affected individuals. Within the Solve-RD consortium, systematic re-analysis of whole exome sequencing (WES) data from unresolved cases with (syndromic) intellectual disability (n = 1,472 probands) was performed. This re-analysis included variant calling of mitochondrial DNA (mtDNA) variants, although mtDNA is not specifically targeted in WES. We identified a functionally relevant mtDNA variant in MT-TL1 (NC_012920.1:m.3291T > C; NC_012920.1:n.62T > C), at a heteroplasmy level of 22% in whole blood, in a 23-year-old male with severe intellectual disability, epilepsy, episodic headaches with emesis, spastic tetraparesis, brain abnormalities, and feeding difficulties. Targeted validation in blood and urine supported pathogenicity, with heteroplasmy levels of 23% and 58% in index, and 4% and 17% in mother, respectively. Interestingly, not all phenotypic features observed in the index have been previously linked to this MT-TL1 variant, suggesting either broadening of the m.3291T > C-associated phenotype, or presence of a co-occurring disorder. Hence, our case highlights the importance of underappreciated mtDNA variants identifiable from WES data, especially for cases with atypical mitochondrial phenotypes and their relatives in the maternal line.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Targeted therapies for metabolic myopathies related to glycogen storage and lipid metabolism: a systematic review and steps towards a 'Treatabolome'

  • Manta, Alexander
  • Spendiff, Sally
  • Lochmüller, Hanns
  • Thompson, Rachel
Background: Metabolic myopathies are a heterogenous group of muscle diseases typically characterized by exercise intolerance, myalgia and progressive muscle weakness. Effective treatments for some of these diseases are available, but while our understanding of the pathogenesis of metabolic myopathies related to glycogen storage, lipid metabolism and β-oxidation is well established, evidence linking treatments with the precise causative genetic defect is lacking. Objective: The objective of this study was to collate all published evidence on pharmacological therapies for the aforementioned metabolic myopathies and link this to the genetic mutation in a format amenable to databasing for further computational use in line with the principles of the "treatabolome" project. Methods: A systematic literature review was conducted to retrieve all levels of evidence examining the therapeutic efficacy of pharmacological treatments on metabolic myopathies related to glycogen storage and lipid metabolism. A key inclusion criterion was the availability of the genetic variant of the treated patients in order to link treatment outcome with the genetic defect. Results: Of the 1,085 articles initially identified, 268 full-text articles were assessed for eligibility, of which 87 were carried over into the final data extraction. The most studied metabolic myopathies were Pompe disease (45 articles), multiple acyl-CoA dehydrogenase deficiency related to mutations in the ETFDH gene (15 articles) and systemic primary carnitine deficiency (8 articles). The most studied therapeutic management strategies for these diseases were enzyme replacement therapy, riboflavin, and carnitine supplementation, respectively. Conclusions: This systematic review provides evidence for treatments of metabolic myopathies linked with the genetic defect in a computationally accessible format suitable for databasing in the treatabolome system, which will enable clinicians to acquire evidence on appropriate therapeutic options for their patient at the time of diagnosis., AM received a Summer Studentship stipend from the Faculty of Medicine at the University of Ottawa. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant NG2-170044 for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). RT receives support from the Canadian Institutes of Health Research (postdoctoral fellowship award MFE-171275). This review is part of the Solve-RD treatabolome initiative. The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Position paper on management of personal data in environment and health research in Europe

  • Govarts, Eva
  • Gilles, Liese
  • Bopp, Stephanie
  • Holub, Petr
  • Matalonga, Leslie
  • Vermeulen, Roel
  • Vrijheid, Martine
  • Beltran, Sergi
  • Hartlev, Mette
  • Jones, Sarah
  • Rodriguez Martin, Laura
  • Standaert, Arnout
  • Swertz, Morris A.
  • Theunis, Jan
  • Trier, Xenia
  • Vogel, Nina
  • Van Espen, Koert
  • Remy, Sylvie
  • Schoeters, Greet
Management of datasets that include health information and other sensitive personal information of European study participants has to be compliant with the General Data Protection Regulation (GDPR, Regulation (EU) 2016/679). Within scientific research, the widely subscribed'FAIR' data principles should apply, meaning that research data should be findable, accessible, interoperable and re-usable. Balancing the aim of open science driven FAIR data management with GDPR compliant personal data protection safeguards is now a common challenge for many research projects dealing with (sensitive) personal data. In December 2020 a workshop was held with representatives of several large EU research consortia and of the European Commission to reflect on how to apply the FAIR data principles for environment and health research (E&H). Several recent data intensive EU funded E&H research projects face this challenge and work intensively towards developing solutions to access, exchange, store, handle, share, process and use such sensitive personal data, with the aim to support European and transnational collaborations. As a result, several recommendations, opportunities and current limitations were formulated. New technical developments such as federated data management and analysis systems, machine learning together with advanced search software, harmonized ontologies and data quality standards should in principle facilitate the FAIRification of data. To address ethical, legal, political and financial obstacles to the wider re-use of data for research purposes, both specific expertise and underpinning infrastructure are needed. There is a need for the E&H research data to find their place in the European Open Science Cloud. Communities using health and population data, environmental data and other publicly available data have to interconnect and synergize. To maximize the use and re-use of environment and health data, a dedicated supporting European infrastructure effort, such as the EIRENE research infrastructure within the ESFRI roadmap 2021, is needed that would interact with existing infrastructures., HBM4EU is co-financed under Horizon 2020 (grant agreement No 733032). EUCAN-Connect is funded by the European Commission within the call topic SC1-BHC-05-2018: “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” (Grant Agreement No 824989). The Canadian project partners have been funded by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec – Santé. The LifeCycle project received funding from the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 733206 LifeCycle). The HELIX project received funding from the European Community’s Seventh Framework Programme (grant agreement no 308333 HELIX). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Roel Vermeulen is supported by EXPOSOME-NL and EXPANSE. EXPOSOME-NL is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.004.017). EXPANSE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874627. EOSC-Life project supported by EU Horizon 2020, grant agreement no. 824087. EJP-RD and Solve-RD projects have been financed under Horizon 2000 (grant numbers H2020 779257 and H2020 825575).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genome-wide variant calling in reanalysis of exome sequencing data uncovered a pathogenic TUBB3 variant

  • Boer, Elke de
  • Yaldiz, Burcu
  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Solve-RD SNV-indel working group
  • Solve-RD-DITF-ITHACA
Almost half of all individuals affected by intellectual disability (ID) remain undiagnosed. In the Solve-RD project, exome sequencing (ES) datasets from unresolved individuals with (syndromic) ID (n = 1,472 probands) are systematically reanalyzed, starting from raw sequencing files, followed by genome-wide variant calling and new data interpretation. This strategy led to the identification of a disease-causing de novo missense variant in TUBB3 in a girl with severe developmental delay, secondary microcephaly, brain imaging abnormalities, high hypermetropia, strabismus and short stature. Interestingly, the TUBB3 variant could only be identified through reanalysis of ES data using a genome-wide variant calling approach, despite being located in protein coding sequence. More detailed analysis revealed that the position of the variant within exon 5 of TUBB3 was not targeted by the enrichment kit, although consistent high-quality coverage was obtained at this position, resulting from nearby targets that provide off-target coverage. In the initial analysis, variant calling was restricted to the exon targets ± 200 bases, allowing the variant to escape detection by the variant calling algorithm. This phenomenon may potentially occur more often, as we determined that 36 established ID genes have robust off-target coverage in coding sequence. Moreover, within these regions, for 17 genes (likely) pathogenic variants have been identified before. Therefore, this clinical report highlights that, although compute-intensive, performing genome-wide variant calling instead of target-based calling may lead to the detection of diagnostically relevant variants that would otherwise remain unnoticed., This work was financially supported by Aspasia grants of the Dutch Research Council (015.014.036 to TK and 015.014.066 to LELMV) and Netherlands Organization for Health Research and Development (917.183.10 to TK). The Solve-RD project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779257.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia

  • Masson, Aymeric
  • Pérez Jurado, Luis Alberto
  • Sevilla-Porras, Marta
  • Vitobello, Antonio
Polypyrimidine tract-binding protein 1 (PTBP1) is a heterogeneous nuclear ribonucleoprotein primarily known for its alternative splicing activity. It shuttles between the nucleus and cytoplasm via partially overlapping N-terminal nuclear localization (NLS) and export (NES) signals. Despite its fundamental role in cell growth and differentiation, its involvement in human disease remains poorly understood. We identified 27 individuals from 25 families harboring de novo or inherited pathogenic variants - predominantly start-loss (89%) and, to a lesser extent, missense (11%) - affecting NES/NLS motifs. Affected individuals presented with a syndromic neurodevelopmental disorder and variable skeletal dysplasia with disproportionate short stature with short limbs. Intellectual functioning ranged from normal to moderately delayed. Start-loss variants led to translation initiation from an alternative downstream in-frame methionine, resulting in loss of the NES and the first half of the bipartite NLS, and increased cytoplasmic stability. Start-loss and missense variants shared a DNA methylation episignature in peripheral blood and altered nucleocytoplasmic distribution in vitro and in vivo with preferential accumulation in processing bodies, causing aberrant gene expression but normal RNA splicing. Transcriptomic analysis of patient-derived fibroblasts revealed dysregulated pathways involved in osteochondrogenesis and neurodevelopment. Overall, our findings highlight a cytoplasmic role for PTBP1 in RNA stability and disease pathogenesis., European Union's Horizon 2020 research and innovation program grant agreement number 779257.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD

  • Sommer, Anna K.
  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Laner, Andreas
  • Holinski-Feder, Elke
  • Steinke-Lange, Verena
  • Peters, Sophia
  • Valle, Laura
  • Spier, Isabel
  • Huntsman, David
  • Solve-RD-GENTURIS group
  • Oliveira, Carla
  • de Voer, Richarda M.
  • Hoogerbrugge, Nicoline
  • Aretz, Stefan
Background: Patients and families with suspected, but genetically unexplained (unsolved) genetic tumour risk syndromes lack appropriate treatment and prevention, leading to preventable morbidity and mortality. To tackle this problem, patients from the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) are analysed in the European Commission's research project "Solving the unsolved rare diseases" (Solve-RD). The aim is to uncover known and novel cancer predisposing genes by reanalysing available whole-exome sequencing (WES) data of large cohorts in a combined manner, and applying a multidimensional omics approach. Approach: Around 500 genetically unsolved cases with suspected hereditary gastrointestinal tumour syndromes (polyposis, early-onset/familial colorectal cancer and gastric cancer) from multiple European centres are aimed to be included. Currently, clinical and germline WES data from 294 cases have been analysed. In addition, an extensive molecular profiling of gastrointestinal tumours from these patients is planned and deep learning techniques will be applied. The ambitious, multidisciplinary project is accompanied by a number of methodical, technical, and logistic challenges, which require the development and implementation of new analysis tools, the standardisation of bioinformatics pipelines, and strategies to exchange data and knowledge. Results: and Outlook. The first re-analysis of 229 known and proposed cancer predisposition genes allowed solving 2-3% of previously unsolved GENTURIS cases. The integration of expert knowledge and new technologies will help to identify the genetic basis of additional unsolved cases within the ongoing project. The ERN GENTURIS approach might serve as a model for other genomic initiatives., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD). This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

  • Lagorce, David
  • Lebreton, Emeline
  • Matalonga, Leslie
  • Hongnat, Oscar
  • Chahdil, Maroua
  • Piscia, Davide
  • Paramonov, Ida
  • Ellwanger, Kornelia
  • Köhler, Sebastian
  • Robinson, Peter N.
  • Graessner, Holm
  • Beltran, Sergi
  • Lucano, Caterina
  • Hanauer, Marc
  • Rath, Ana
Data de publicació electrònica: 06-11-2023, Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)'s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Standards of NGS data sharing and analysis in Ataxias: recommendations by the NGS Working Group of the Ataxia Global Initiative

  • Beijer, Danique
  • Fogel, Brent L.
  • Beltran, Sergi
  • Danzi, Matt C.
  • Németh, Andrea H.
  • Züchner, Stephan
  • Synofzik, Matthis
  • AGI Ataxia NGS genomics, platforms Working Group
The Ataxia Global Initiative (AGI) is a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias. The next-generation sequencing (NGS) working group of the AGI aims to improve methods, platforms, and international standards for ataxia NGS analysis and data sharing, ultimately allowing to increase the number of genetically ataxia patients amenable for natural history and treatment trials. Despite extensive implementation of NGS for ataxia patients in clinical and research settings, the diagnostic gap remains sizeable, as approximately 50% of patients with hereditary ataxia remain genetically undiagnosed. One current shortcoming is the fragmentation of patients and NGS datasets on different analysis platforms and databases around the world. The AGI NGS working group in collaboration with the AGI associated research platforms—CAGC, GENESIS, and RD-Connect GPAP—provides clinicians and scientists access to user-friendly and adaptable interfaces to analyze genome-scale patient data. These platforms also foster collaboration within the ataxia community. These efforts and tools have led to the diagnosis of > 500 ataxia patients and the discovery of > 30 novel ataxia genes. Here, the AGI NGS working group presents their consensus recommendations for NGS data sharing initiatives in the ataxia field, focusing on harmonized NGS variant analysis and standardized clinical and metadata collection, combined with collaborative data and analysis tool sharing across platforms., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Horizon 2020 research and innovation programme (grant 779257 Solve-RD to MS and SB), and the European Joint Programme on Rare Diseases (grant 825575 EJP RD to SB) under the EJP RD COFUND-EJP No. 825575 (PROSPAX consortium, to MS and—as an associated partner—SZ). DB is supported by a Postdoctoral Fellowship from the Alexander von Humboldt Foundation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Wnt genes in colonic polyposis predisposition

  • Quintana, Isabel
  • Tonda, Raúl
  • Parra Farré, Genís
  • Piscia, Davide
  • Beltran, Sergi
  • Valle, Laura
This research was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), and co-funded by FEDER funds a way to build Europe [Grants No. SAF2016-80888-R (LV), PID2020-112595RB-I00 (LV), and PID2019-111254RB-I00 (GC), and predoctoral fellowship “Formación de Personal Investigador” (IQ)]; Instituto de Salud Carlos III [CIBERONC CB16/12/00234, Sara Borrell Postdoctoral contract (PM)]; Government of Catalonia, Spain [PERIS MedPerCan, AGAUR 2017SGR1282, CERCA Program for institutional support]; Scientific Foundation “Asociación Española Contra el Cáncer” [AECC Investigador (MT)]; Marie Skłodowska-Curie Individual Fellowship [Organ-VIP; Grant agreement No. 897064 (NG-A)]. The Solve-RD project is funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 779257. This study was supported by the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) - Project ID No. 739547 (www.genturis.eu), and the COST action CA17118, supported by COST (European Cooperation in Science and Technology).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Recommendations for whole genome sequencing in diagnostics for rare diseases

  • Souche, Erika
  • Beltran, Sergi
  • Weiss, Marjan M.
In 2016, guidelines for diagnostic Next Generation Sequencing (NGS) have been published by EuroGentest in order to assist laboratories in the implementation and accreditation of NGS in a diagnostic setting. These guidelines mainly focused on Whole Exome Sequencing (WES) and targeted (gene panels) sequencing detecting small germline variants (Single Nucleotide Variants (SNVs) and insertions/deletions (indels)). Since then, Whole Genome Sequencing (WGS) has been increasingly introduced in the diagnosis of rare diseases as WGS allows the simultaneous detection of SNVs, Structural Variants (SVs) and other types of variants such as repeat expansions. The use of WGS in diagnostics warrants the re-evaluation and update of previously published guidelines. This work was jointly initiated by EuroGentest and the Horizon2020 project Solve-RD. Statements from the 2016 guidelines have been reviewed in the context of WGS and updated where necessary. The aim of these recommendations is primarily to list the points to consider for clinical (laboratory) geneticists, bioinformaticians, and (non-)geneticists, to provide technical advice, aid clinical decision-making and the reporting of the results., This work was supported by the Solve-RD project (European Union’s Horizon 2020 grant agreement No 779257) to MS, SB, OR and CG, and the National Centre for medical genomics (www.ncmg.cz, CZ.02.1.01/0.0/0.0/16_026/000844, LM2018132 (MSMT.cz) and 00064203/6003 (MZCR.cz) to MM). OR received financial support from Illumina for implementing whole genome sequencing into clinical diagnostics (Ge-Med project)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Homozygous WASHC4 variant in two sisters causes a syndromic phenotype defined by dysmorphisms, intellectual disability, profound developmental disorder, and skeletal muscle involvement

  • Gangfuß, Andrea
  • Czech, Artur
  • Hentschel, Andreas
  • Münchberg, Ute
  • Horvath, Rita
  • Töpf, Ana
  • O'Heir, Emily
  • Lochmüller, Hanns
  • Stehling, Florian
  • Kiewert, Cordula
  • Sickmann, Albert
  • Kuechler, Alma
  • Kaiser, Frank J.
  • Kölbel, Heike
  • Christiansen, Jon
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
Recessive variants in WASHC4 are linked to intellectual disability complicated by poor language skills, short stature, and dysmorphic features. The protein encoded by WASHC4 is part of the Wiskott-Aldrich syndrome protein and SCAR homolog family, co-localizes with actin in cells, and promotes Arp2/3-dependent actin polymerization in vitro. Functional studies in a zebrafish model suggested that WASHC4 knockdown may also affect skeletal muscles by perturbing protein clearance. However, skeletal muscle involvement has not been reported so far in patients, and precise biochemical studies allowing a deeper understanding of the molecular etiology of the disease are still lacking. Here, we report two siblings with a homozygous WASHC4 variant expanding the clinical spectrum of the disease and provide a phenotypical comparison with cases reported in the literature. Proteomic profiling of fibroblasts of the WASHC4-deficient patient revealed dysregulation of proteins relevant for the maintenance of the neuromuscular axis. Immunostaining on a muscle biopsy derived from the same patient confirmed dysregulation of proteins relevant for proper muscle function, thus highlighting an affliction of muscle cells upon loss of functional WASHC4. The results of histological and coherent anti-Stokes Raman scattering microscopic studies support the concept of a functional role of the WASHC4 protein in humans by altering protein processing and clearance. The proteomic analysis confirmed key molecular players in vitro and highlighted, for the first time, the involvement of skeletal muscle in patients. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland., This study was supported by four authors of this publication who are members of the European Reference Network for Neuromuscular Diseases – Project ID No 870177. This study was supported also by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin – Senatskanzlei Wissenschaft und Forschung’, and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz Research Cluster (grant number 031A360E). This work was also supported by a grant from the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. RH was supported by the European Research Council (309548), a Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Parts of this study were financed within the framework of the NME-GPS project by the European Regional Development Fund (ERDF). AT is supported by the Horizon 2020 research and innovation program via grant 779257 ‘Solve-RD’. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome

  • Atalaia, Antonio
  • Corvò, Alberto
  • Piscia, Davide
  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Laurie, Steven, 1973-
  • Lochmüller, Hanns
  • Bonne, Gisèle
Background: Rare diseases are individually rare but globally affect around 6% of the population, and in over 70% of cases are genetically determined. Their rarity translates into a delayed diagnosis, with 25% of patients waiting 5 to 30 years for one. It is essential to raise awareness of patients and clinicians of existing gene and variant-specific therapeutics at the time of diagnosis to avoid that treatment delays add up to the diagnostic odyssey of rare diseases' patients and their families. Aims: This paper aims to provide guidance and give detailed instructions on how to write homogeneous systematic reviews of rare diseases' treatments in a manner that allows the capture of the results in a computer-accessible form. The published results need to comply with the FAIR guiding principles for scientific data management and stewardship to facilitate the extraction of datasets that are easily transposable into machine-actionable information. The ultimate purpose is the creation of a database of rare disease treatments ("Treatabolome") at gene and variant levels as part of the H2020 research project Solve-RD. Results: Each systematic review follows a written protocol to address one or more rare diseases in which the authors are experts. The bibliographic search strategy requires detailed documentation to allow its replication. Data capture forms should be built to facilitate the filling of a data capture spreadsheet and to record the application of the inclusion and exclusion criteria to each search result. A PRISMA flowchart is required to provide an overview of the processes of search and selection of papers. A separate table condenses the data collected during the Systematic Review, appraised according to their level of evidence. Conclusions: This paper provides a template that includes the instructions for writing FAIR-compliant systematic reviews of rare diseases' treatments that enables the assembly of a Treatabolome database that complement existing diagnostic and management support tools with treatment awareness data., The current paper was written for the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A de novo CSDE1 variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents

  • Gangfuß, Andrea
  • Lochmüller, Hanns
  • Töpf, Ana
  • O'Hehir, Emily
  • Horvath, Rita
  • Kölbel, Heike
  • Schweiger, Bernd
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
CSDE1 encodes the cytoplasmic cold shock domain-containing protein E1 (CSDE1), which is highly conserved across species and functions as an RNA-binding protein involved in translationally coupled mRNA turnover. CSDE1 displays a bidirectional role: promoting and repressing the translation of RNAs but also increasing and decreasing the abundance of RNAs. Preclinical studies highlighted an involvement of CSDE1 in different forms of cancer. Moreover, CSDE1 is highly expressed in human embryonic stem cells and plays a role in neuronal migration and differentiation. A genome-wide association study suggested CSDE1 as a potential autism-spectrum disorder risk gene. A multicenter next generation sequencing approach unraveled likely causative heterozygous variants in CSDE1 in 18 patients, identifying a new autism spectrum disorder-related syndrome consisting of autism, intellectual disability, and neurodevelopmental delay. Since then, no further patients with CSDE1 variants have been reported in the literature. Here, we report a 9.5-year-old girl from a consanguineous family of Turkish origin suffering from profound delayed speech and motor development, moderate intellectual disability, neurologic and psychiatric symptoms as well as hypoplasia of corpus callosum and mildly reduced brain volume on brain magnetic resonance imaging associated with a recurrent de novo mutation in CSDE1 (c.367C > T; p.R123*) expanding the phenotypical spectrum associated with pathogenic CSDE1 variants., Funding: Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1) and the Lily Foundation and the Evelyn Trust. Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

  • Thompson, Rachel
  • Bonne, Gisèle
  • Missier, Paolo
  • Lochmüller, Hanns
Despite recent scientific advances, most rare genetic diseases - including most neuro-muscular diseases - do not currently have curative gene-based therapies available. However, in some cases, such as vitamin, cofactor or enzyme deficiencies, channelopathies and disorders of the neuromuscular junction, a confirmed genetic diagnosis provides guidance on treatment, with drugs available that may significantly alter the disease course, improve functional ability and extend life expectancy. Nevertheless, many treatable patients remain undiagnosed or do not receive treatment even after genetic diagnosis. The growth of computer-aided genetic analysis systems that enable clinicians to diagnose their undiagnosed patients has not yet been matched by genetics-based decision-support systems for treatment guidance. Generating a 'treatabolome' of treatable variants and the evidence for the treatment has the potential to increase treatment rates for treatable conditions. Here, we use the congenital myasthenic syndromes (CMS), a group of clinically and genetically heterogeneous but frequently treatable neuromuscular conditions, to illustrate the steps in the creation of a treatabolome for rare inherited diseases. We perform a systematic review of the evidence for pharmacological treatment of each CMS type, gathering evidence from 207 studies of over 1000 patients and stratifying by genetic defect, as treatment varies depending on the underlying cause. We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider., H.L. and R.T. received support from the EU under RD-Connect [FP7 Grant Agreement No. 305444] and the U.K. Medical Research Council [G1002274/98482]. G.B. receives support under the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 [H2020 Grant Agreement No. 779257].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs correlate with corticosteroid response in duchenne muscular dystrophy

  • Passarelli, Chiara
  • Lochmüller, Hanns
  • Ferlini, Alessandra
Background: Duchenne muscular dystrophy (DMD) is a rare and severe X-linked muscular dystrophy in which the standard of care with variable outcome, also due to different drug response, is chronic off-label treatment with corticosteroids (CS). In order to search for SNP biomarkers for corticosteroid responsiveness, we genotyped variants across 205 DMD-related genes in patients with differential response to steroid treatment. Methods and findings: We enrolled a total of 228 DMD patients with identified dystrophin mutations, 78 of these patients have been under corticosteroid treatment for at least 5 years. DMD patients were defined as high responders (HR) if they had maintained the ability to walk after 15 years of age and low responders (LR) for those who had lost ambulation before the age of 10 despite corticosteroid therapy. Based on interactome mapping, we prioritized 205 genes and sequenced them in 21 DMD patients (discovery cohort or DiC = 21). We identified 43 SNPs that discriminate between HR and LR. Discriminant Analysis of Principal Components (DAPC) prioritized 2 response-associated SNPs in the TNFRSF10A gene. Validation of this genotype was done in two additional larger cohorts composed of 46 DMD patients on corticosteroid therapy (validation cohorts or VaC1), and 150 non ambulant DMD patients and never treated with corticosteroids (VaC2). SNP analysis in all validation cohorts (N = 207) showed that the CT haplotype is significantly associated with HR DMDs confirming the discovery results. Conclusion: We have shown that TNFRSF10A CT haplotype correlates with corticosteroid response in DMD patients and propose it as an exploratory CS response biomarker., The EU BIO-NMD project no. 241665 and the SOLVE-RD project (H2020 ID: 779257) were supported this study. FM was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. The support of the Muscular Dystrophy UK to the Dubowitz Neuromuscular Centre and of the MRC Neuromuscular Centre and BRC Biobank is also gratefully acknowledged. Part of this study was also supported by the NIHR grant “Rare Diseases Translational Research Collaboration” on Duchenne muscular dystrophy to FM. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The EUROBIOBANK, European Network of DNA, Cell and Tissue Banks for Rare Diseases was also acknowledged.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer

  • São José, Celina
  • Laurie, Steven, 1973-
  • Oliveira, Carla
Background: Germline CDH1 pathogenic or likely pathogenic variants cause hereditary diffuse gastric cancer (HDGC). Once a genetic cause is identified, stomachs' and breasts' surveillance and/or prophylactic surgery is offered to asymptomatic CDH1 carriers, which is life-saving. Herein, we characterized an inherited mechanism responsible for extremely early-onset gastric cancer and atypical HDGC high penetrance. Methods: Whole-exome sequencing (WES) re-analysis was performed in an unsolved HDGC family. Accessible chromatin and CDH1 promoter interactors were evaluated in normal stomach by ATAC-seq and 4C-seq, and functional analysis was performed using CRISPR-Cas9, RNA-seq and pathway analysis. Results: We identified a germline heterozygous 23 Kb CDH1-TANGO6 deletion in a family with eight diffuse gastric cancers, six before age 30. Atypical HDGC high penetrance and young cancer-onset argued towards a role for the deleted region downstream of CDH1, which we proved to present accessible chromatin, and CDH1 promoter interactors in normal stomach. CRISPR-Cas9 edited cells mimicking the CDH1-TANGO6 deletion display the strongest CDH1 mRNA downregulation, more impacted adhesion-associated, type-I interferon immune-associated and oncogenic signalling pathways, compared to wild-type or CDH1-deleted cells. This finding solved an 18-year family odyssey and engaged carrier family members in a cancer prevention pathway of care. Conclusion: In this work, we demonstrated that regulatory elements lying down-stream of CDH1 are part of a chromatin network that control CDH1 expression and influence cell transcriptome and associated signalling pathways, likely explaining high disease penetrance and very young cancer-onset. This study highlights the importance of incorporating scientific-technological updates and clinical guidelines in routine diagnosis, given their impact in timely genetic diagnosis and disease prevention., This work received funding from: (1) the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257 (Solve‐RD: H2020-SC1-2017-Single-Stage-RTD), which provided Ph.D. salaries to JG-P, AS, ItP; (2) The European Regional Development Fund (ERDF) through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Inovação (LEGOH: PTDC/BTM-TEC/6706/2020); (3) FCT with salary support for Ph.D. studentships to CSJ (Ref. SFRH/BD/140796/2018), JG-P (Ref. 2022.11952.BD) and MF (Ref. 2020.05763.BD); (4) MT is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). Open access funding provided by FCT|FCCN (b-on).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation

  • Sušak, Hana, 1985-
  • Serra Saurina, Laura
  • Demidov, German, 1990-
  • Rabionet Janssen, Raquel
  • Domènech Salgado, Laura, 1989-
  • Bosio, Mattia
  • Muyas Remolar, Francesc, 1992-
  • Estivill, Xavier, 1955-
  • Escaramís, Geòrgia
  • Ossowski, Stephan
Rare variants are thought to play an important role in the etiology of complex diseases and may explain a significant fraction of the missing heritability in genetic disease studies. Next-generation sequencing facilitates the association of rare variants in coding or regulatory regions with complex diseases in large cohorts at genome-wide scale. However, rare variant association studies (RVAS) still lack power when cohorts are small to medium-sized and if genetic variation explains a small fraction of phenotypic variance. Here we present a novel Bayesian rare variant Association Test using Integrated Nested Laplace Approximation (BATI). Unlike existing RVAS tests, BATI allows integration of individual or variant-specific features as covariates, while efficiently performing inference based on full model estimation. We demonstrate that BATI outperforms established RVAS methods on realistic, semi-synthetic whole-exome sequencing cohorts, especially when using meaningful biological context, such as functional annotation. We show that BATI achieves power above 70% in scenarios in which competing tests fail to identify risk genes, e.g. when risk variants in sum explain less than 0.5% of phenotypic variance. We have integrated BATI, together with five existing RVAS tests in the 'Rare Variant Genome Wide Association Study' (rvGWAS) framework for data analyzed by whole-exome or whole genome sequencing. rvGWAS supports rare variant association for genes or any other biological unit such as promoters, while allowing the analysis of essential functionalities like quality control or filtering. Applying rvGWAS to a Chronic Lymphocytic Leukemia study we identified eight candidate predisposition genes, including EHMT2 and COPS7A., Funding: SO, HS, XE, FM and GD received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635290 (PanCanRisk). SO and GD received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257 (Solve-RD). RR received support from the Fundació La Marató 70/307:201726. HS, GD, RR, LD, MB, FM, XE, GE and SO received support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017, and the CERCA Programme / Generalitat de Catalunya
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources

  • Köhler, Sebastian
  • Beltran, Sergi
  • Lochmüller, Hanns
The Human Phenotype Ontology (HPO)-a standardized vocabulary of phenotypic abnormalities associated with 7000+ diseases-is used by thousands of researchers, clinicians, informaticians and electronic health record systems around the world. Its detailed descriptions of clinical abnormalities and computable disease definitions have made HPO the de facto standard for deep phenotyping in the field of rare disease. The HPO's interoperability with other ontologies has enabled it to be used to improve diagnostic accuracy by incorporating model organism data. It also plays a key role in the popular Exomiser tool, which identifies potential disease-causing variants from whole-exome or whole-genome sequencing data. Since the HPO was first introduced in 2008, its users have become both more numerous and more diverse. To meet these emerging needs, the project has added new content, language translations, mappings and computational tooling, as well as integrations with external community data. The HPO continues to collaborate with clinical adopters to improve specific areas of the ontology and extend standardized disease descriptions. The newly redesigned HPO website (www.human-phenotype-ontology.org) simplifies browsing terms and exploring clinical features, diseases, and human genes., National Institutes of Health (NIH), Monarch Initiative [OD #5R24OD011883]; Forums for Integrative Phenomics [U13 CA221044-01]; NCATS Data Translator [1OT3TR002019]; NCATS National Center for Digital Health Informatics Innovation [U24 TR002306]; NIH Data Commons [1 OT3 OD02464-01 UNCCH]; Cost Action CA 16118 Neuro-MIG; British Heart Foundation Programme Grant [RG/13/5/30112]; Division of Intramural Research; NIAID; NIH; E-RARE project Hipbi-RD [01GM1608]; European Union’s Horizon 2020 Research and Innovation Programme [779257]. Funding for open access charge: NIH; Donald A. Roux Family Fund (to P.N.R.).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mobile element insertions in rare diseases: a comparative benchmark and reanalysis of 60,000 exome samples

  • Wijngaard, Robin
  • Laurie, Steven, 1973-
  • Gilissen, Christian
Mobile element insertions (MEIs) are a known cause of genetic disease but have been underexplored due to technical limitations of genetic testing methods. Various bioinformatic tools have been developed to identify MEIs in Next Generation Sequencing data. However, most tools have been developed specifically for genome sequencing (GS) data rather than exome sequencing (ES) data, which remains more widely used for routine diagnostic testing. In this study, we benchmarked six MEI detection tools (ERVcaller, MELT, Mobster, SCRAMble, TEMP2 and xTea) on ES data and on GS data from publicly available genomic samples (HG002, NA12878). For all the tools we evaluated sensitivity and precision of different filtering strategies. Results show that there were substantial differences in tool performance between ES and GS data. MELT performed best with ES data and its combination with SCRAMble increased substantially the detection rate of MEIs. By applying both tools to 10,890 ES samples from Solve-RD and 52,624 samples from Radboudumc we were able to diagnose 10 patients who had remained undiagnosed by conventional ES analysis until now. Our study shows that MELT and SCRAMble can be used reliably to identify clinically relevant MEIs in ES data. This may lead to an additional diagnosis for 1 in 3000 to 4000 patients in routine clinical ES., Funding The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 779257. RW received an international fellowship from the José Luis Castaño-SEQC Foundation. FM is supported by the Edmond J. Safra Foundation through the Edmond J. Safra Fellowship in Movement Disorders.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1)

  • Töpf, Ana
  • Pyle, Angela
  • Griffin, Helen
  • Matalonga, Leslie
  • Schon, Katherine
  • Solve-RD SNV-indel working group
  • Solve-RD DITF-euroNMD
  • Sickmann, Albert
  • Schara-Schmidt, Ulrike
  • Hentschel, Andreas
  • Chinnery, Patrick F.
  • Kölbel, Heike
  • Roos, Andreas
TRIP4 is one of the subunits of the transcriptional coregulator ASC-1, a ribonucleoprotein complex that participates in transcriptional coactivation and RNA processing events. Recessive variants in the TRIP4 gene have been associated with spinal muscular atrophy with bone fractures as well as a severe form of congenital muscular dystrophy. Here we present the diagnostic journey of a patient with cerebellar hypoplasia and spinal muscular atrophy (PCH1) and congenital bone fractures. Initial exome sequencing analysis revealed no candidate variants. Reanalysis of the exome data by inclusion in the Solve-RD project resulted in the identification of a homozygous stop-gain variant in the TRIP4 gene, previously reported as disease-causing. This highlights the importance of analysis reiteration and improved and updated bioinformatic pipelines. Proteomic profile of the patient's fibroblasts showed altered RNA-processing and impaired exosome activity supporting the pathogenicity of the detected variant. In addition, we identified a novel genetic form of PCH1, further strengthening the link of this characteristic phenotype with altered RNA metabolism., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Several authors of this study are members of the European Reference Network for Neuromuscular disease, Project ID No 739543. This study was supported by the AFM (grant 21644 to AR), the framework of the NME-GPS project by the European Regional Development Fund (AR/US/AS), the support by the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin-inkl. Wissenschaft und Forschung, and the Bundesministerium für Bildung und Forschung (AH and AS), the European Research Council (RH), the Wellcome Investigator Award (109915/Z/15/Z to RH), the Medical Research Council UK (MR/N025431/1 to RH), the Newton Fund (MR/N027302/1 to RH), the Lily Foundation (RH) and the Evelyn Trust (RH). This research was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1 and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era

  • Thompson, Rachel
  • Abicht, Angela
  • Beeson, David
  • Engel, Andrew G.
  • Eymard, Bruno
  • Maxime, Emmanuel
  • Lochmüller, Hanns
Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes., RT and HL received funding from the European Union, FP7 Grant No. 30544: RD-Connect and Horizon 2020 Grant No. 779257: Solve-RD, and the UK Medical Research Council (MRC) Centre for Neuromuscular Diseases (G1002274, grant ID 98482). AE received funding from NIH Grant NS109491. The funding bodies had no role in study design or execution or in writing the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases

  • Zurek, Birte
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Solve-RD Consortium
For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient's data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This research is supported (not financially) by four ERNs: (1) The ERN for Intellectual Disability, Telehealth and Congenital Anomalies (ERN-ITHACA)—Project ID No 869189; (2) The ERN on Rare Neurological Diseases (ERN-RND)—Project ID No 739510; (3) The ERN for Neuromuscular Diseases (ERN Euro-NMD)—Project ID No 870177; (4) The ERN on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. The ERNs are co-funded by the European Union within the framework of the Third Health Programme.
Repisalud
Publication Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
Repisalud
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernández-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raul
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Rémi
  • Alonso, Angel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J
  • Cañada-Pallarés, Andrés
  • Fernández, José M
  • Hansson, Mats G
  • Horvath, Rita
  • Jacobsen, Julius O B
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • Lopez-Martin, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis Alberto
  • Posada De la Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A C
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo G
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.
Repisalud
Publication Artículo científico (JournalArticle)

Model matchmaking via the Solve-RD Rare Disease Models & Mechanisms Network (RDMM-Europe)

  • Ellwanger, Kornelia
  • Brill, Julie A
  • de Boer, Elke
  • Efthymiou, Stephanie
  • Elgersma, Ype
  • Icmat, Marynelle
  • Lecoquierre, François
  • Lobato, Amanda G
  • Morleo, Manuela
  • Ori, Michela
  • Schaffer, Ashleigh E
  • Vitobello, Antonio
  • Wells, Sara
  • Yalcin, Binnaz
  • Zhai, R Grace
  • Sturm, Marc
  • Zurek, Birte
  • Graessner, Holm
  • Bermejo-Sanchez, Eva
  • Evangelista, Teresinha
  • Hoogerbrugge, Nicoline
  • Nigro, Vincenzo
  • Schüle, Rebecca
  • Verloes, Alain
  • Brunner, Han
  • Campeau, Philippe M
  • Lasko, Paul
  • Riess, Olaf
In biomedical research, particularly for rare diseases (RDs), there is a critical need for model organisms to unravel the mechanistic basis of diseases, perform biomarker studies and develop potential therapeutic interventions. Within Solve-RD, an EU-funded research project with the aim of solving large numbers of previously unsolved RDs, the European Rare Disease Models & Mechanisms Network (RDMM-Europe) has been established.
Repisalud
Publication Artículo científico (JournalArticle)

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases

  • Zurek, Birte
  • Ellwanger, Kornelia
  • Vissers, Lisenka E L M
  • Schüle, Rebecca
  • Synofzik, Matthis
  • Töpf, Ana
  • de Voer, Richarda M
  • Laurie, Steven
  • Matalonga, Leslie
  • Gilissen, Christian
  • Ossowski, Stephan
  • t Hoen, Peter A C
  • Vitobello, Antonio
  • Schulze-Hentrich, Julia M
  • Riess, Olaf
  • Brunner, Han G
  • Brookes, Anthony J
  • Rath, Ana
  • Bonne, Gisèle
  • Gumus, Gulcin
  • Verloes, Alain
  • Hoogerbrugge, Nicoline
  • Evangelista, Teresinha
  • Harmuth, Tina
  • Swertz, Morris
  • Spalding, Dylan
  • Hoischen, Alexander
  • Beltran, Sergi
  • Graessner, Holm
  • Solve-RD consortium
  • Posada De la Paz, Manuel
  • Bermejo-Sanchez, Eva
  • Lopez-Martin, Estrella
  • Martinez-Delgado, Beatriz
For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient's data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe.
Repisalud
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández-Ferrer, Carles
  • Piscia, Davide
  • Schüle, Rebecca
  • Synofzik, Matthis
  • Töpf, Ana
  • Vissers, Lisenka E L M
  • de Voer, Richarda
  • Tonda, Raul
  • Laurie, Steven
  • Fernández-Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvó, Alberto
  • Joshi, Ricky
  • Diez, Hector
  • Gut, Ivo
  • Hoischen, Alexander
  • Graessner, Holm
  • Beltran, Sergi
  • Solve-RD Consortia
  • Cuesta de la Plaza, Isabel
  • Lopez-Martin, Estrella
  • Posada De la Paz, Manuel
  • Bermejo-Sanchez, Eva
  • Martinez-Delgado, Beatriz
  • Alonso, Javier
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.
Repisalud
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • de Boer, Elke
  • Jackson, Adam
  • Benetti, Elisa
  • Banka, Siddharth
  • Bruel, Ange-Line
  • Ciolfi, Andrea
  • Clayton-Smith, Jill
  • Dallapiccola, Bruno
  • Duffourd, Yannis
  • Ellwanger, Kornelia
  • Fallerini, Chiara
  • Gilissen, Christian
  • Graessner, Holm
  • Haack, Tobias B
  • Havlovicova, Marketa
  • Hoischen, Alexander
  • Jean-Marçais, Nolwenn
  • Kleefstra, Tjitske
  • Lopez-Martin, Estrella
  • Macek, Milan
  • Mencarelli, Maria Antonietta
  • Moutton, Sébastien
  • Pfundt, Rolph
  • Pizzi, Simone
  • Posada De la Paz, Manuel
  • Radio, Francesca Clementina
  • Renieri, Alessandra
  • Rooryck, Caroline
  • Ryba, Lukas
  • Safraou, Hana
  • Schwarz, Martin
  • Tartaglia, Marco
  • Thauvin-Robinet, Christel
  • Thevenon, Julien
  • Tran Mau-Them, Frederic
  • Trimouille, Aurélien
  • Votypka, Pavel
  • de Vries, Bert B A
  • Willemsen, Marjolein H
  • Zurek, Birte
  • Verloes, Alain
  • Philippe, Christophe
  • Vitobello, Antonio
  • Vissers, Lisenka E L M
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock.
Repisalud
Publication Artículo científico (JournalArticle)

A MT-TL1 variant identified by whole exome sequencing in an individual with intellectual disability, epilepsy, and spastic tetraparesis

  • de Boer, Elke
  • Ockeloen, Charlotte W
  • Matalonga, Leslie
  • Horvath, Rita
  • Solve-RD SNV-indel working group
  • Rodenburg, Richard J
  • Coenen, Marieke J H
  • Janssen, Mirian
  • Henssen, Dylan
  • Gilissen, Christian
  • Steyaert, Wouter
  • Paramonov, Ida
  • Solve-RD-DITF-ITHACA
  • Trimouille, Aurélien
  • Kleefstra, Tjitske
  • Verloes, Alain
  • Vissers, Lisenka E L M
  • Posada De la Paz, Manuel
The genetic etiology of intellectual disability remains elusive in almost half of all affected individuals. Within the Solve-RD consortium, systematic re-analysis of whole exome sequencing (WES) data from unresolved cases with (syndromic) intellectual disability (n = 1,472 probands) was performed. This re-analysis included variant calling of mitochondrial DNA (mtDNA) variants, although mtDNA is not specifically targeted in WES. We identified a functionally relevant mtDNA variant in MT-TL1 (NC_012920.1:m.3291T > C; NC_012920.1:n.62T > C), at a heteroplasmy level of 22% in whole blood, in a 23-year-old male with severe intellectual disability, epilepsy, episodic headaches with emesis, spastic tetraparesis, brain abnormalities, and feeding difficulties. Targeted validation in blood and urine supported pathogenicity, with heteroplasmy levels of 23% and 58% in index, and 4% and 17% in mother, respectively. Interestingly, not all phenotypic features observed in the index have been previously linked to this MT-TL1 variant, suggesting either broadening of the m.3291T > C-associated phenotype, or presence of a co-occurring disorder. Hence, our case highlights the importance of underappreciated mtDNA variants identifiable from WES data, especially for cases with atypical mitochondrial phenotypes and their relatives in the maternal line.
Repisalud
Publication Artículo científico (JournalArticle)

Genome-wide variant calling in reanalysis of exome sequencing data uncovered a pathogenic TUBB3 variant

  • de Boer, Elke
  • Yaldiz, Burcu
  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Laurie, Steve
  • Solve-RD SNV-indel working group
  • Solve-RD-DITF-ITHACA
  • Cuesta de la Plaza, Isabel
  • Posada De la Paz, Manuel
Almost half of all individuals affected by intellectual disability (ID) remain undiagnosed. In the Solve-RD project, exome sequencing (ES) datasets from unresolved individuals with (syndromic) ID (n = 1,472 probands) are systematically reanalyzed, starting from raw sequencing files, followed by genome-wide variant calling and new data interpretation. This strategy led to the identification of a disease-causing de novo missense variant in TUBB3 in a girl with severe developmental delay, secondary microcephaly, brain imaging abnormalities, high hypermetropia, strabismus and short stature. Interestingly, the TUBB3 variant could only be identified through reanalysis of ES data using a genome-wide variant calling approach, despite being located in protein coding sequence. More detailed analysis revealed that the position of the variant within exon 5 of TUBB3 was not targeted by the enrichment kit, although consistent high-quality coverage was obtained at this position, resulting from nearby targets that provide off-target coverage. In the initial analysis, variant calling was restricted to the exon targets ± 200 bases, allowing the variant to escape detection by the variant calling algorithm. This phenomenon may potentially occur more often, as we determined that 36 established ID genes have robust off-target coverage in coding sequence. Moreover, within these regions, for 17 genes (likely) pathogenic variants have been identified before. Therefore, this clinical report highlights that, although compute-intensive, performing genome-wide variant calling instead of target-based calling may lead to the detection of diagnostically relevant variants that would otherwise remain unnoticed.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raúl
  • Bayés, Mónica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean Remí
  • Alonso Sánchez, Ángel Miguel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J.
  • Cañada-Pallarés, Andrés
  • Fernández, José M.
  • Hansson, Mats G.
  • Horvath, Rita
  • Jacobsen, Julius O. B.
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • López-Martín, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis A.
  • Posada-de-la-Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N.
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A. C.
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltrán, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation

  • Susak, Hana
  • Serra-Saurina, Laura
  • Demidov, German
  • Rabionet Janssen, Raquel
  • Domènech, Laura
  • Bosio, Mattia
  • Muyas, Francesc
  • Estivill, Xavier, 1955-
  • Escaramís Babiano, Geòrgia
  • Ossowski, Stephan
Rare variants are thought to play an important role in the etiology of complex diseases and may explain a significant fraction of the missing heritability in genetic disease studies. Next-generation sequencing facilitates the association of rare variants in coding or regulatory regions with complex diseases in large cohorts at genome-wide scale. However, rare variant association studies (RVAS) still lack power when cohorts are small to medium-sized and if genetic variation explains a small fraction of phenotypic variance. Here we present a novel Bayesian rare variant Association Test using Integrated Nested Laplace Approximation (BATI). Unlike existing RVAS tests, BATI allows integration of individual or variant-specific features as covariates, while efficiently performing inference based on full model estimation. We demonstrate that BATI outperforms established RVAS methods on realistic, semi-synthetic whole-exome sequencing cohorts, especially when using meaningful biological context, such as functional annotation. We show that BATI achieves power above 70% in scenarios in which competing tests fail to identify risk genes, e.g. when risk variants in sum explain less than 0.5% of phenotypic variance. We have integrated BATI, together with five existing RVAS tests in the 'Rare Variant Genome Wide Association Study' (rvGWAS) framework for data analyzed by whole-exome or whole genome sequencing. rvGWAS supports rare variant association for genes or any other biological unit such as promoters, while allowing the analysis of essential functionalities like quality control or filtering. Applying rvGWAS to a Chronic Lymphocytic Leukemia study we identified eight candidate predisposition genes, including EHMT2 and COPS7A.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Page, Angela
  • Smith, Lindsay
  • Adams, Jeremy B.
  • Alterovitz, Gil
  • Babb, Lawrence J.
  • Barkley, Maxmillian P.
  • Baudis, Michael
  • Beauvais, Michael J. S.
  • Beck, Tim
  • Beckmann, Jacques S.
  • Varma, Susheel
  • Vears, Danya F.
  • Viner, Coby
  • Voisin, Craig
  • Wagner, Alex H.
  • Wallace, Susan E.
  • Walsh, Brian P.
  • Williams, Marc S.
  • Winkler, Eva C.
  • Brudno, Michael
  • Kelleher, Jerome
  • Wold, Barbara J.
  • Wood, Grant M.
  • Woolley, J. Patrick
  • Yamasaki, Chisato
  • Yates, Andrew D.
  • Yung, Christina K.
  • Zass, Lyndon J.
  • Zaytseva, Ksenia
  • Zhang, Junjun
  • Goodhand, Peter
  • Kerry, Giselle
  • Brush,Matthew H.
  • North, Kathryn
  • Birney, Ewan
  • Bujold, David
  • Burdett, Tony
  • Buske, Orion J.
  • Cabili, Moran N.
  • Cameron, Daniel L.
  • Carroll, Robert J.
  • Casas-Silva, Esmeralda
  • Khor, Seik-Soon
  • Chakravarty, Debyani
  • Chaudhari, Bimal P.
  • Chen, Shu Hui
  • Cherry, J. Michael
  • Chung, Justina
  • Cline, Melissa
  • Clissold, Hayley L.
  • Cook-Deegan, Robert M.
  • Courtot, Melanie
  • Cunningham, Fiona
  • Knoppers, Bartha M.
  • Cupak, Miro
  • Davies, Robert M.
  • Denisko, Danielle
  • Doerr, Megan J.
  • Dolman, Lena I.
  • Dove, Edward S.
  • Dursi, Lewis Jonathan
  • Dyke, Stephanie O. M.
  • Eddy, James A.
  • Eilbeck, Karen
  • Konopko, Melissa A.
  • Ellrott, Kyle P.
  • Fairley, Susan
  • Fakhro, Khalid A.
  • Firth, Helen V.
  • Fitzsimons, Michael S.
  • Fiume, Marc
  • Flicek, Paul
  • Fore, Ian M.
  • Freeberg, Mallory A.
  • Freimuth, Robert R.
  • Kosaki, Kenjiro
  • Fromont, Lauren A.
  • Fuerth, Jonathan
  • Gaff, Clara L.
  • Gan, Weiniu
  • Ghanaim, Elena M.
  • Glazer, David
  • Green, Robert C.
  • Griffith, Malachi
  • Griffith, Obi L.
  • Grossman, Robert L.
  • Kuba, Martin
  • Groza, Tudor
  • Guidry Auvil, Jaime M.
  • Guigó, Roderic
  • Gupta, Dipayan
  • Haendel, Melissa A.
  • Hamosh, Ada
  • Hansen, David P.
  • Hart, Reece K.
  • Hartley, Dean Mitchell
  • Haussler, David
  • Lawson, Jonathan
  • Hendricks-Sturrup, Rachele M.
  • Ho, Calvin W. L.
  • Hobb, Ashley E.
  • Hoffman, Michael M.
  • Hofmann, Oliver M.
  • Holub, Petr
  • Shujui Hsu, Jacob
  • Hubaux, Jean-Pierre
  • Hunt, Sarah E.
  • Husami, Ammar
  • Leinonen, Rasko
  • Jacobsen, Julius O.
  • Jamuar, Saumya S.
  • Janes, Elizabeth L.
  • Jeanson, Francis
  • Jene, Aina
  • Johns, Amber L.
  • Joly, Yann
  • Jones, Steven J. M.
  • Kanitz, Alexander
  • Kato, Kazuto
  • Li, Stephanie
  • Keane, Thomas M.
  • Kekesi-Lafrance, Kristina
  • Beltran, Sergi
  • Lin, Michael F.
  • Linden, Mikael
  • Liu, Xianglin
  • Udara Liyanage, Isuru
  • López, Javier
  • Lucassen, Anneke M.
  • Lukowski, Michael
  • Mann, Alice L.
  • Marshall, John
  • Mattioni, Michele
  • Bernick, David
  • Metke-Jiménez, Alejandro
  • Middleton, Anna
  • Milne, Richard J.
  • Molnár-Gábor, Fruzsina
  • Mulder, Nicola
  • Muñoz-Torres, Mónica C.
  • Nag, Rishi
  • Nakagawa, Hidewaki
  • Nasir, Jamal
  • Navarro, Arcadi
  • Bernier, Alexander
  • Nelson, Tristan H.
  • Niewielska, Ania
  • Nisselle, Amy
  • Niu, Jeffrey
  • Nyrönen, Tommi H.
  • O’Connor, Brian D.
  • Oesterle, Sabine
  • Ogishima, Soichi
  • Wang, Vivian Ota
  • Paglione, Laura A. D.
  • Bonfield, James K.
  • Palumbo, Emilio
  • Parkinson, Helen E.
  • Philippakis, Anthony A.
  • Pizarro, Angel D.
  • Prlic, Andreas
  • Rambla, Jordi
  • Rendon, Augusto
  • Rider, Renee A.
  • Robinson, Peter N.
  • Rodarmer, Kurt W.
  • Boughtwood, Tiffany F.
  • Lyman Rodríguez, Laura
  • Rubin, Alan F.
  • Rueda, Manuel
  • Rushton, Gregory A.
  • Ryan, Rosalyn S.
  • Saunders, Gary I.
  • Schuilenburg, Helen
  • Schwede, Torsten
  • Scollen, Serena
  • Senf, Alexander
  • Bourque, Guillaume
  • Sheffield, Nathan C.
  • Skantharajah, Neerjah
  • Smith, Albert V.
  • Sofia, Heidi J.
  • Spalding, Dylan
  • Spurdle, Amanda B.
  • Stark, Zornitza
  • Stein, Lincoln D.
  • Suematsu, Makoto
  • Tan, Patrick
  • Bowers, Sarion R.
  • Tedds, Jonathan A.
  • Thomson, Alastair A.
  • Thorogood, Adrian
  • Tickle, Timothy L.
  • Tokunaga, Katsushi
  • Törnroos,Juha
  • Torrents, David
  • Upchurch, Sean
  • Valencia, Alfonso
  • Valls Guimera, Roman
  • Brookes, Anthony J.
  • Vamathevan, Jessica
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients

  • Traschütz, Andreas
  • Adarmes-Gómez, Astrid
  • Anheim, Mathieu
  • Baets, Jonathan
  • Falkenburger, Björn H.
  • Gburek-Augustat, Janina
  • Doss, Sarah
  • Kamm, Christoph
  • Klivenyi, Peter
  • Grobe-Einsler, Marcus
  • Klopstock, Thomas
  • Minnerop, Martina
  • Münchau, Alexander
  • Pane, Chiara
  • Renaud, Mathilde
  • Santorelli, Filippo M.
  • Schöls, Ludger
  • Timmann, Dagmar
  • Vielhaber, Stefan
  • Haack, Tobias B.
  • Warrenburg, Bart van de
  • Zanni, Ginevra
  • Synofzik, Matthis
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., This work was supported by the European Union's Horizon 2020 research and innovation program as part of the innovation project EVIDENCE-RND under the EJP RD COFUND-EJP (825575 to M.S.), as part of Solve-RD (779257 to J.B., M.S., and B.P.v.d.W.), by the DFG under the frame of EJP-RD network PROSPAX (441409627 to M.S. and B.P.v.d.W.), and by the Clinician Scientist program “PRECISE.net” funded by the Else Kröner-Fresenius-Stiftung (to A.T.). The study was further funded by the Federal Ministry of Education and Research, Germany, and through the TreatHSP network (01GM1905 to L.S.). B.P.v.d.W. receives additional research support from ZonMW, NWO, Hersenstichting, Brugling fonds, Gossweiler Foundation, and Radboud university medical center. L.S., T.K., G.Z., B.P.v.d.W., and M.S. are members of the European Reference Network for Rare Neurological Diseases—Project ID 739510. A.T. receives funding from the University of Tübingen, medical faculty, for the Clinician Scientist Program Grant 439-0-0. P.K. receives funding from University of Szeged (Hetényi Géza: 5S330 A202) and Ministry of Innovation and Technology of Hungary, National Research, Development and Innovation Fund (TKP2021-EGA). J.B. was supported by a Senior Clinical Researcher mandate of the Research Fund—Flanders (FWO) under grant agreement number 1805021N and is a member of the μNEURO Research Centre of Excellence of the University of Antwerp. F.M.S. was supported by the Italian Ministry of Health (the EJP-RD network PROSPAX; Ricerca Finalizzata RF-2016-02361610; RF-2019-12370417; Ricerca Corrente, RC 5x1000). Several authors of this publication are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and of the European Reference Network for Rare Neurological Diseases (ERN-RND). Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders

  • Gracia-Díaz, Carolina
  • Zhou, Yijing
  • Yang, Qian
  • Maroofian, Reza
  • España-Bonilla, Paula
  • Lee, Chul-Hwan
  • Zhang, Shuo
  • Padilla, Natàlia
  • Fueyo, Raquel
  • Waxman, Elisa A.
  • Lei, Sunyimeng
  • Otrimski, Garrett
  • Li, Dong
  • Sheppard, Sarah E.
  • Mark, Paul
  • Harr, Margaret H.
  • Hakonarson, Hakon
  • Rodan, Lance
  • Jackson, Adam
  • Vasudevan, Pradeep
  • Powel, Corrina
  • Mohammed, Shehla
  • Maddirevula, Sateesh
  • Alzaidan, Hamad
  • Faqeih, Eissa A.
  • Efthymiou, Stephanie
  • Turchetti, Valentina
  • Rahman, Fátima
  • Maqbool, Shazia
  • Salpietro, Vincenzo
  • Ibrahim, Shahnaz H.
  • di Rosa, Gabriella
  • Houlden, Henry
  • Alharbi, Maha Nasser
  • Al-Sannaa, Nouriya Abbas
  • Bauer, Peter
  • Zifarelli, Giovanni
  • Estaras, Conchi
  • Hurst, Anna C. E.
  • Thompson, Michelle L.
  • Chassevent, Anna
  • Smith-Hicks, Constance L.
  • Cruz, Xavier de la
  • Holtz, Alexander M.
  • Elloumi, Houda Zghal
  • Hajianpour, M. J.
  • Rieubland, Claudine
  • Braun, Dominique
  • Banka, Siddharth
  • French, Deborah L.
  • Heller, Elizabeth A.
  • Saade, Murielle
  • Song, Hongjun
  • Ming, Guo-Li
  • Alkuraya, Fowzan S.
  • Agrawal, Pankaj B.
  • Reinberg, Danny
  • Bhoj, Elizabeth J.
  • Martínez-Balbás, Marian
  • Akizu, Naiara
Genetic variants in chromatin regulators are frequently found in neurodevelopmental disorders, but their effect in disease etiology is rarely determined. Here, we uncover and functionally define pathogenic variants in the chromatin modifier EZH1 as the cause of dominant and recessive neurodevelopmental disorders in 19 individuals. EZH1 encodes one of the two alternative histone H3 lysine 27 methyltransferases of the PRC2 complex. Unlike the other PRC2 subunits, which are involved in cancers and developmental syndromes, the implication of EZH1 in human development and disease is largely unknown. Using cellular and biochemical studies, we demonstrate that recessive variants impair EZH1 expression causing loss of function effects, while dominant variants are missense mutations that affect evolutionarily conserved aminoacids, likely impacting EZH1 structure or function. Accordingly, we found increased methyltransferase activity leading to gain of function of two EZH1 missense variants. Furthermore, we show that EZH1 is necessary and sufficient for differentiation of neural progenitor cells in the developing chick embryo neural tube. Finally, using human pluripotent stem cell-derived neural cultures and forebrain organoids, we demonstrate that EZH1 variants perturb cortical neuron differentiation. Overall, our work reveals a critical role of EZH1 in neurogenesis regulation and provides molecular diagnosis for previously undefined neurodevelopmental disorders., This work was supported by the CHOP/UPENN IDDRC-New Program Development award, CHOP-Junior Faculty Pilot Program award, Margaret Q Landerbergen Foundation Award and NIH/NINDS R01NS119699, NIH/NICHD R21HD107592 (to N.A.), NIH/NINDS R35NS116843 (to H.S.), NIH/NINDS R35NS097370 and NIH/NIMH RF1MH123979 (to G.-l.M.)., BFU2015-69248-P and PGC2018-096082-B-I00 from the Spanish Ministry of Economy (to M.A.M.B.), Alabama Genomic Health Initiative F170303004 through University of Alabama at Birmingham (to A.C.H., M.T.), PID2019-111217RB-I00 Spanish Ministerio de Ciencia e Innovación (to X.D.L.C.), ID2019-110157RA-I00 (to M.S.), FPU Spanish Ministry of Education and Science predoctoral fellowship (to R.F.) and 2021 FISDU 00400 (to P.E-B.), NIHR Manchester Biomedical Research Centre NIHR203308 and Solve-RD which is supported by the European Union’s Horizon 2020 research and innovation program grant agreement No 779257 (to S.B.). This research was made possible through access to the data and findings generated by the 100KGP and the DDD. The 100KGP is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100KGP is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100KGP uses data provided by patients and collected by the National Health Service as part of their care and support. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. The views expressed in this publication are those of the author(s) and not necessarily those of Wellcome or the Department of Health. The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD

  • Sommer, Anna K.
  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Laner, Andreas
  • Holinski-Feder, Elke
  • Steinke-Lange, Verena
  • Peters, Sophia
  • Valle, Laura
  • Spier, Isabel
  • Huntsman, David
  • Solve-RD-GENTURIS group
  • Oliveira, Carla
  • de Voer, Richarda M.
  • Hoogerbrugge, Nicoline
  • Aretz, Stefan
Background: Patients and families with suspected, but genetically unexplained (unsolved) genetic tumour risk syndromes lack appropriate treatment and prevention, leading to preventable morbidity and mortality. To tackle this problem, patients from the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) are analysed in the European Commission's research project "Solving the unsolved rare diseases" (Solve-RD). The aim is to uncover known and novel cancer predisposing genes by reanalysing available whole-exome sequencing (WES) data of large cohorts in a combined manner, and applying a multidimensional omics approach. Approach: Around 500 genetically unsolved cases with suspected hereditary gastrointestinal tumour syndromes (polyposis, early-onset/familial colorectal cancer and gastric cancer) from multiple European centres are aimed to be included. Currently, clinical and germline WES data from 294 cases have been analysed. In addition, an extensive molecular profiling of gastrointestinal tumours from these patients is planned and deep learning techniques will be applied. The ambitious, multidisciplinary project is accompanied by a number of methodical, technical, and logistic challenges, which require the development and implementation of new analysis tools, the standardisation of bioinformatics pipelines, and strategies to exchange data and knowledge. Results: and Outlook. The first re-analysis of 229 known and proposed cancer predisposition genes allowed solving 2-3% of previously unsolved GENTURIS cases. The integration of expert knowledge and new technologies will help to identify the genetic basis of additional unsolved cases within the ongoing project. The ERN GENTURIS approach might serve as a model for other genomic initiatives., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD). This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19

  • Solanich, Xavier
  • Vargas-Parra, Gardenia
  • Van der Made, Caspar I.
  • Simons, Annet
  • Schuurs-Hoeijmakers, Janneke
  • Antolí, Arnau
  • Del Valle, Jesús
  • Rocamora-Blanch, Gemma
  • Setién, Fernando
  • Esteller, Manel
  • Van Reijmersdal, Simon V.
  • Riera-Mestre, Antoni
  • Sabater-Riera, Joan
  • Capellà, Gabriel
  • Van de Veerdonk, Frank L.
  • Van der Hoven, Ben
  • Corbella Virós, Xavier
  • Hoischen, Alexander
  • Lázaro, Conxi
Contract grant sponsor: Supported by La Marató de TV3 foundation (202115-30-31), the Carlos III National Health Institute funded by FEDER funds – a way to build Europe –[PI19/00553 and CIBERONC]; the Government of Catalonia [2017SGR1282 and 2017SGR496]. AH is supported by the SolveRD project. The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 779257. FV was supported by a ZonMW (The Netherlands Organization for Health Research and Development) Vidi grant (No. 91718351). This research was part of the Netherlands X-omics Initiative and partially funded by NWO (The Netherlands Organization for Scientific Research; project 184.034.019)., Introduction: Loss-of-function TLR7 variants have been recently reported in a small number of males to underlie strong predisposition to severe COVID-19. We aimed to determine the presence of these rare variants in young men with severe COVID-19. Methods: We prospectively studied males between 18 and 50 years-old without predisposing comorbidities that required at least high-flow nasal oxygen to treat COVID-19. The coding region of TLR7 was sequenced to assess the presence of potentially deleterious variants. Results: TLR7 missense variants were identified in two out of 14 patients (14.3%). Overall, the median age was 38 (IQR 30-45) years. Both variants were not previously reported in population control databases and were predicted to be damaging by in silico predictors. In a 30-year-old patient a maternally inherited variant [c.644A>G; p.(Asn215Ser)] was identified, co-segregating in his 27-year-old brother who also contracted severe COVID-19. A second variant [c.2797T>C; p.(Trp933Arg)] was found in a 28-year-old patient, co-segregating in his 24-year-old brother who developed mild COVID-19. Functional testing of this variant revealed decreased type I and II interferon responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist imiquimod, confirming a loss-of-function effect. Conclusions: This study supports a rationale for the genetic screening for TLR7 variants in young men with severe COVID-19 in the absence of other relevant risk factors. A diagnosis of TLR7 deficiency could not only inform on treatment options for the patient, but also enables pre-symptomatic testing of at-risk male relatives with the possibility of instituting early preventive and therapeutic interventions., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Piscia, Davide
  • Tonda, Raúl
  • Laurie, Steven, 1973-
  • Fernández Callejo, Marcos
  • Picó, Daniel
  • Garcia-Linares, Carles
  • Papakonstantinou, Anastasios
  • Corvò, Alberto
  • Joshi, Ricky S.
  • Diez, Hector
  • Gut, Ivo Glynne
  • Beltran, Sergi
  • Solve-RD Consortium
Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP's Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo Glynne
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform and URD-Cat Data Contributors
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines., Supported by European Union projects RD-Connect, Solve-RD, and European Joint Programme of Rare Diseases (EJP-RD) grants FP7 305444, H2020 779257, and H2020 825575; Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática; ELIXIR Implementation Studies; European Union projects BBMRI-LPC EU FP7 313010, NeurOmics EU FP7 305121, and Undiagnosed Rare Disease Program of Catalonia (Departament de Salut, Generalitat de CatalunyaSLT002/16/00174); Canadian Institutes of Health Research Foundation grant FDN-167281 (H.L.); the European Research Council309548 (R.H.); the Wellcome Investigator Award 109915/Z/15/Z (R.H.); the Medical Research Council (United Kingdom) MR/N025431/1 (R.H.); the Wellcome Trust Pathfinder Scheme 201064/Z/16/Z (R.H. and H.L.); the Newton Fund (United Kingdom/Turkey) MR/N027302/1 (R.H. and H.L.); the Spanish Ministry of Economy, Industry and Competitiveness to the European Molecular Biology Laboratory (EMBL) partnership; the Centro de Excelencia Severo Ochoa; the Centres de Recerca de Catalunya (CERCA) Program/Generalitat de Catalunya; the Generalitat de Catalunya through the Department of Health and Department of Business and Knowledge; the Spanish Ministry of Economy, Industry and Competitiveness with funds from the European Regional Development Fund corresponding to the 2014 to 2020 Smart Growth Operating Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion

  • McMacken, Grace M.
  • Lochmüller, Hanns
  • Bansagi, Boglarka
  • Pyle, Angela
  • Lochmüller, Angela
  • Chinnery, Patrick F.
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Matalonga, Leslie
  • Horvath, Rita
Background: Behr syndrome is a clinically distinct, but genetically heterogeneous disorder characterized by optic atrophy, progressive spastic paraparesis, and motor neuropathy often associated with ataxia. The molecular diagnosis is based on gene panel testing or whole-exome/genome sequencing. Methods: Here, we report the clinical presentation of two siblings with a novel genetic form of Behr syndrome. We performed whole-exome sequencing in the two patients and their mother. Results: Both patients had a childhood-onset, slowly progressive disease resembling Behr syndrome, starting with visual impairment, followed by progressive spasticity, weakness, and atrophy of the lower legs and ataxia. They also developed scoliosis, leading to respiratory problems. In their late 30's, both siblings developed a hypertrophic cardiomyopathy and died of sudden cardiac death at age 43 and 40, respectively. Whole-exome sequencing identified the novel homozygous c.627_629del; p.(Gly210del) deletion in UCHL1. Conclusions: The presentation of our patients raises the possibility that hypertrophic cardiomyopathy may be an additional feature of the clinical syndrome associated with UCHL1 mutations, and highlights the importance of cardiac follow-up and treatment in neurodegenerative disease associated with UCHL1 mutations., The study was supported by the Newton Fund UK/Turkey (MR/N027302/1 to HL and RH), the Medical Research Council (UK) (MR/N025431/1 to RH), the Wellcome Investigator fund (109915/Z/15/Z to RH), the Lily Foundation UK (to RH), the European Research Council (309548 to RH), and the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z to HL and RH). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD”. Data were analyzed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement no. 305444).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Recommendations for whole genome sequencing in diagnostics for rare diseases

  • Souche, Erika
  • Beltran, Sergi
  • Weiss, Marjan M.
In 2016, guidelines for diagnostic Next Generation Sequencing (NGS) have been published by EuroGentest in order to assist laboratories in the implementation and accreditation of NGS in a diagnostic setting. These guidelines mainly focused on Whole Exome Sequencing (WES) and targeted (gene panels) sequencing detecting small germline variants (Single Nucleotide Variants (SNVs) and insertions/deletions (indels)). Since then, Whole Genome Sequencing (WGS) has been increasingly introduced in the diagnosis of rare diseases as WGS allows the simultaneous detection of SNVs, Structural Variants (SVs) and other types of variants such as repeat expansions. The use of WGS in diagnostics warrants the re-evaluation and update of previously published guidelines. This work was jointly initiated by EuroGentest and the Horizon2020 project Solve-RD. Statements from the 2016 guidelines have been reviewed in the context of WGS and updated where necessary. The aim of these recommendations is primarily to list the points to consider for clinical (laboratory) geneticists, bioinformaticians, and (non-)geneticists, to provide technical advice, aid clinical decision-making and the reporting of the results., This work was supported by the Solve-RD project (European Union’s Horizon 2020 grant agreement No 779257) to MS, SB, OR and CG, and the National Centre for medical genomics (www.ncmg.cz, CZ.02.1.01/0.0/0.0/16_026/000844, LM2018132 (MSMT.cz) and 00064203/6003 (MZCR.cz) to MM). OR received financial support from Illumina for implementing whole genome sequencing into clinical diagnostics (Ge-Med project)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Position paper on management of personal data in environment and health research in Europe

  • Govarts, Eva
  • Gilles, Liese
  • Bopp, Stephanie
  • Holub, Petr
  • Matalonga, Leslie
  • Vermeulen, Roel
  • Vrijheid, Martine
  • Beltran, Sergi
  • Hartlev, Mette
  • Jones, Sarah
  • Rodriguez Martin, Laura
  • Standaert, Arnout
  • Swertz, Morris A.
  • Theunis, Jan
  • Trier, Xenia
  • Vogel, Nina
  • Van Espen, Koert
  • Remy, Sylvie
  • Schoeters, Greet
Management of datasets that include health information and other sensitive personal information of European study participants has to be compliant with the General Data Protection Regulation (GDPR, Regulation (EU) 2016/679). Within scientific research, the widely subscribed'FAIR' data principles should apply, meaning that research data should be findable, accessible, interoperable and re-usable. Balancing the aim of open science driven FAIR data management with GDPR compliant personal data protection safeguards is now a common challenge for many research projects dealing with (sensitive) personal data. In December 2020 a workshop was held with representatives of several large EU research consortia and of the European Commission to reflect on how to apply the FAIR data principles for environment and health research (E&H). Several recent data intensive EU funded E&H research projects face this challenge and work intensively towards developing solutions to access, exchange, store, handle, share, process and use such sensitive personal data, with the aim to support European and transnational collaborations. As a result, several recommendations, opportunities and current limitations were formulated. New technical developments such as federated data management and analysis systems, machine learning together with advanced search software, harmonized ontologies and data quality standards should in principle facilitate the FAIRification of data. To address ethical, legal, political and financial obstacles to the wider re-use of data for research purposes, both specific expertise and underpinning infrastructure are needed. There is a need for the E&H research data to find their place in the European Open Science Cloud. Communities using health and population data, environmental data and other publicly available data have to interconnect and synergize. To maximize the use and re-use of environment and health data, a dedicated supporting European infrastructure effort, such as the EIRENE research infrastructure within the ESFRI roadmap 2021, is needed that would interact with existing infrastructures., HBM4EU is co-financed under Horizon 2020 (grant agreement No 733032). EUCAN-Connect is funded by the European Commission within the call topic SC1-BHC-05-2018: “International flagship collaboration with Canada for human data storage, integration and sharing to enable personalized medicine approaches” (Grant Agreement No 824989). The Canadian project partners have been funded by the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec – Santé. The LifeCycle project received funding from the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 733206 LifeCycle). The HELIX project received funding from the European Community’s Seventh Framework Programme (grant agreement no 308333 HELIX). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Roel Vermeulen is supported by EXPOSOME-NL and EXPANSE. EXPOSOME-NL is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.004.017). EXPANSE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874627. EOSC-Life project supported by EU Horizon 2020, grant agreement no. 824087. EJP-RD and Solve-RD projects have been financed under Horizon 2000 (grant numbers H2020 779257 and H2020 825575).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome

  • Atalaia, Antonio
  • Corvò, Alberto
  • Piscia, Davide
  • Matalonga, Leslie
  • Hernández Ferrer, Carles
  • Laurie, Steven, 1973-
  • Lochmüller, Hanns
  • Bonne, Gisèle
Background: Rare diseases are individually rare but globally affect around 6% of the population, and in over 70% of cases are genetically determined. Their rarity translates into a delayed diagnosis, with 25% of patients waiting 5 to 30 years for one. It is essential to raise awareness of patients and clinicians of existing gene and variant-specific therapeutics at the time of diagnosis to avoid that treatment delays add up to the diagnostic odyssey of rare diseases' patients and their families. Aims: This paper aims to provide guidance and give detailed instructions on how to write homogeneous systematic reviews of rare diseases' treatments in a manner that allows the capture of the results in a computer-accessible form. The published results need to comply with the FAIR guiding principles for scientific data management and stewardship to facilitate the extraction of datasets that are easily transposable into machine-actionable information. The ultimate purpose is the creation of a database of rare disease treatments ("Treatabolome") at gene and variant levels as part of the H2020 research project Solve-RD. Results: Each systematic review follows a written protocol to address one or more rare diseases in which the authors are experts. The bibliographic search strategy requires detailed documentation to allow its replication. Data capture forms should be built to facilitate the filling of a data capture spreadsheet and to record the application of the inclusion and exclusion criteria to each search result. A PRISMA flowchart is required to provide an overview of the processes of search and selection of papers. A separate table condenses the data collected during the Systematic Review, appraised according to their level of evidence. Conclusions: This paper provides a template that includes the instructions for writing FAIR-compliant systematic reviews of rare diseases' treatments that enables the assembly of a Treatabolome database that complement existing diagnostic and management support tools with treatment awareness data., The current paper was written for the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

  • Lagorce, David
  • Lebreton, Emeline
  • Matalonga, Leslie
  • Hongnat, Oscar
  • Chahdil, Maroua
  • Piscia, Davide
  • Paramonov, Ida
  • Ellwanger, Kornelia
  • Köhler, Sebastian
  • Robinson, Peter N.
  • Graessner, Holm
  • Beltran, Sergi
  • Lucano, Caterina
  • Hanauer, Marc
  • Rath, Ana
Data de publicació electrònica: 06-11-2023, Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)'s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A de novo CSDE1 variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents

  • Gangfuß, Andrea
  • Lochmüller, Hanns
  • Töpf, Ana
  • O'Hehir, Emily
  • Horvath, Rita
  • Kölbel, Heike
  • Schweiger, Bernd
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
CSDE1 encodes the cytoplasmic cold shock domain-containing protein E1 (CSDE1), which is highly conserved across species and functions as an RNA-binding protein involved in translationally coupled mRNA turnover. CSDE1 displays a bidirectional role: promoting and repressing the translation of RNAs but also increasing and decreasing the abundance of RNAs. Preclinical studies highlighted an involvement of CSDE1 in different forms of cancer. Moreover, CSDE1 is highly expressed in human embryonic stem cells and plays a role in neuronal migration and differentiation. A genome-wide association study suggested CSDE1 as a potential autism-spectrum disorder risk gene. A multicenter next generation sequencing approach unraveled likely causative heterozygous variants in CSDE1 in 18 patients, identifying a new autism spectrum disorder-related syndrome consisting of autism, intellectual disability, and neurodevelopmental delay. Since then, no further patients with CSDE1 variants have been reported in the literature. Here, we report a 9.5-year-old girl from a consanguineous family of Turkish origin suffering from profound delayed speech and motor development, moderate intellectual disability, neurologic and psychiatric symptoms as well as hypoplasia of corpus callosum and mildly reduced brain volume on brain magnetic resonance imaging associated with a recurrent de novo mutation in CSDE1 (c.367C > T; p.R123*) expanding the phenotypical spectrum associated with pathogenic CSDE1 variants., Funding: Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Andreas Roos received funding from The French Muscular Dystrophy Association (AFM-Téléthon) (grant 21644). Andreas Roos, Andrea Gangfuß, and Ulrike Schara-Schmidt also acknowledge funding in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). Rita Horvath was supported by the European Research Council (309548), the Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), the Newton Fund (UK/Turkey, MR/N027302/1) and the Lily Foundation and the Evelyn Trust. Hanns Lochmüller receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research, and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). AT is supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD.” Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects

  • Arlt, Annabelle
  • Kohlschmidt, Nicolai
  • Hentschel, Andreas
  • Bartels, Enrika
  • Groß, Claudia
  • Töpf, Ana
  • Edem, Pinar
  • Szabo, Nora
  • Sickmann, Albert
  • Meyer, Nancy
  • Schara-Schmidt, Ulrike
  • Lau, Jarred
  • Lochmüller, Hanns
  • Horvath, Rita
  • Oktay, Yavuz
  • Roos, Andreas
  • Hiz, Semra
Background: Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. Results: We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Conclusions: Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS., Open Access funding enabled and organized by Projekt DEAL. We gratefully acknowledge the financial support by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen and the Bundesministerium für Bildung und Forschung. This work was also supported by a Grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. Parts of this study were financed in the framework of the NME-GPS project by the European Regional Development Fund (ERDF). The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. The Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. Sequencing and analysis of patient 2 were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute Grant UM1 HG008900 and in part by National Human Genome Research Institute Grant R01 HG009141. Sequencing of patient 1 was carried out through the Biobanking and Biomedical Resources Research Infrastructure ‐ large prospective cohorts (BBMRI‐LPC) 2016 access call for Whole Exome Sequencing (FP7/2007‐2013), Grant Number: 313010. Data was analyzed using the RD‐Connect Genome‐Phenome Analysis platform developed under FP7/2007‐2013 funded project, Grant Number: 305444. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The study was further supported by the Horizon 2020 research and innovation program via Grant 779257 “Solve-RD” (RH and HL). USS, RH and HL are members of the European Reference Network for Rare Neuromuscular Diseases (EURO-NMD). YO is supported by the Turkish Academy of Sciences’ Young Investigator Award (TÜBA-GEBIP).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Remote visualization of large-scale genomic alignments for collaborative clinical research and diagnosis of rare diseases

  • Corvò, Alberto
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Picó-Amador, Daniel
  • Fernández Callejo, Marcos
  • Paramonov, Ida
  • Gut, Ivo Glynne
  • Piscia, Davide
  • Beltran, Sergi
The Solve-RD project objectives include solving undiagnosed rare diseases (RD) through collaborative research on shared genome-phenome datasets. The RD-Connect Genome-Phenome Analysis Platform (GPAP), for data collation and analysis, and the European Genome-Phenome Archive (EGA), for file storage, are two key components of the Solve-RD infrastructure. Clinical researchers can identify candidate genetic variants within the RD-Connect GPAP and, thanks to the developments presented here as part of joint ELIXIR activities, are able to remotely visualize the corresponding alignments stored at the EGA. The Global Alliance for Genomics and Health (GA4GH) htsget streaming application programming interface (API) is used to retrieve alignment slices, which are rendered by an integrated genome viewer (IGV) instance embedded in the GPAP. As a result, it is no longer necessary for over 11,000 datasets to download large alignment files to visualize them locally. This work highlights the advantages, from both the user and infrastructure perspectives, of implementing interoperability standards for establishing federated genomics data networks., This study was partially funded by ELIXIR Implementation Studies “Remote real-time visualization of human RDs genomics data (RD-Connect) stored at the EGA ELIXIR” (2017–2018), “Integration of ELIXIR-IIB in ELIXIR Rare Disease activities (2017–2018),” and “Rare Disease Infrastructure ELIXIR (2019–2020)” and the Solve-RD project, which received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which has received funding from EU projects RD-Connect, Solve-RD, and EJP-RD (grant nos. FP7 305444, H2020 779257, and H2020 825575), Instituto de Salud Carlos III (grant nos. PT13/0001/0044 and PT17/0009/0019; Instituto Nacional de Bioinformática, INB), and ELIXIR Implementation Studies. We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity

  • Matalonga Borrel, Lesley
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez Jurado, Luis A.
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert Jan
  • Lochmüller, Hanns
  • Beltrán, Sergi
  • Rare Disease-Connect Genome-Phenome Analysis Platform data contributors
  • Undiagnosed Rare Disease Programme of Catalonia data contibutors
  • Cormand Rifà, Bru
  • Balcells Comas, Susana
  • Grinberg Vaisman, Daniel Raúl
  • Urreizti, Roser
  • Garrabou Tornos, Glòria
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

  • Thompson, Rachel
  • Bonne, Gisèle
  • Missier, Paolo
  • Lochmüller, Hanns
Despite recent scientific advances, most rare genetic diseases - including most neuro-muscular diseases - do not currently have curative gene-based therapies available. However, in some cases, such as vitamin, cofactor or enzyme deficiencies, channelopathies and disorders of the neuromuscular junction, a confirmed genetic diagnosis provides guidance on treatment, with drugs available that may significantly alter the disease course, improve functional ability and extend life expectancy. Nevertheless, many treatable patients remain undiagnosed or do not receive treatment even after genetic diagnosis. The growth of computer-aided genetic analysis systems that enable clinicians to diagnose their undiagnosed patients has not yet been matched by genetics-based decision-support systems for treatment guidance. Generating a 'treatabolome' of treatable variants and the evidence for the treatment has the potential to increase treatment rates for treatable conditions. Here, we use the congenital myasthenic syndromes (CMS), a group of clinically and genetically heterogeneous but frequently treatable neuromuscular conditions, to illustrate the steps in the creation of a treatabolome for rare inherited diseases. We perform a systematic review of the evidence for pharmacological treatment of each CMS type, gathering evidence from 207 studies of over 1000 patients and stratifying by genetic defect, as treatment varies depending on the underlying cause. We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider., H.L. and R.T. received support from the EU under RD-Connect [FP7 Grant Agreement No. 305444] and the U.K. Medical Research Council [G1002274/98482]. G.B. receives support under the Solve-RD project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 [H2020 Grant Agreement No. 779257].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era

  • Thompson, Rachel
  • Abicht, Angela
  • Beeson, David
  • Engel, Andrew G.
  • Eymard, Bruno
  • Maxime, Emmanuel
  • Lochmüller, Hanns
Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes., RT and HL received funding from the European Union, FP7 Grant No. 30544: RD-Connect and Horizon 2020 Grant No. 779257: Solve-RD, and the UK Medical Research Council (MRC) Centre for Neuromuscular Diseases (G1002274, grant ID 98482). AE received funding from NIH Grant NS109491. The funding bodies had no role in study design or execution or in writing the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A MT-TL1 variant identified by whole exome sequencing in an individual with intellectual disability, epilepsy, and spastic tetraparesis

  • de Boer, Elke
  • Ockeloen, Charlotte W.
  • Matalonga, Leslie
  • Horvath, Rita
  • Solve-RD SNV-indel working group
  • Rodenburg, Richard J.
  • Coenen, Marieke J.H.
  • Janssen, Mirian
  • Henssen, Dylan
  • Gilissen, Christian
  • Steyaert, Wouter
  • Paramonov, Ida
  • Solve-RD-DITF-ITHACA
  • Trimouille, Aurélien
  • Kleefstra, Tjitske
  • Verloes, Alain
  • Vissers, Lisenka E.L.M.
The genetic etiology of intellectual disability remains elusive in almost half of all affected individuals. Within the Solve-RD consortium, systematic re-analysis of whole exome sequencing (WES) data from unresolved cases with (syndromic) intellectual disability (n = 1,472 probands) was performed. This re-analysis included variant calling of mitochondrial DNA (mtDNA) variants, although mtDNA is not specifically targeted in WES. We identified a functionally relevant mtDNA variant in MT-TL1 (NC_012920.1:m.3291T > C; NC_012920.1:n.62T > C), at a heteroplasmy level of 22% in whole blood, in a 23-year-old male with severe intellectual disability, epilepsy, episodic headaches with emesis, spastic tetraparesis, brain abnormalities, and feeding difficulties. Targeted validation in blood and urine supported pathogenicity, with heteroplasmy levels of 23% and 58% in index, and 4% and 17% in mother, respectively. Interestingly, not all phenotypic features observed in the index have been previously linked to this MT-TL1 variant, suggesting either broadening of the m.3291T > C-associated phenotype, or presence of a co-occurring disorder. Hence, our case highlights the importance of underappreciated mtDNA variants identifiable from WES data, especially for cases with atypical mitochondrial phenotypes and their relatives in the maternal line.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs correlate with corticosteroid response in duchenne muscular dystrophy

  • Passarelli, Chiara
  • Lochmüller, Hanns
  • Ferlini, Alessandra
Background: Duchenne muscular dystrophy (DMD) is a rare and severe X-linked muscular dystrophy in which the standard of care with variable outcome, also due to different drug response, is chronic off-label treatment with corticosteroids (CS). In order to search for SNP biomarkers for corticosteroid responsiveness, we genotyped variants across 205 DMD-related genes in patients with differential response to steroid treatment. Methods and findings: We enrolled a total of 228 DMD patients with identified dystrophin mutations, 78 of these patients have been under corticosteroid treatment for at least 5 years. DMD patients were defined as high responders (HR) if they had maintained the ability to walk after 15 years of age and low responders (LR) for those who had lost ambulation before the age of 10 despite corticosteroid therapy. Based on interactome mapping, we prioritized 205 genes and sequenced them in 21 DMD patients (discovery cohort or DiC = 21). We identified 43 SNPs that discriminate between HR and LR. Discriminant Analysis of Principal Components (DAPC) prioritized 2 response-associated SNPs in the TNFRSF10A gene. Validation of this genotype was done in two additional larger cohorts composed of 46 DMD patients on corticosteroid therapy (validation cohorts or VaC1), and 150 non ambulant DMD patients and never treated with corticosteroids (VaC2). SNP analysis in all validation cohorts (N = 207) showed that the CT haplotype is significantly associated with HR DMDs confirming the discovery results. Conclusion: We have shown that TNFRSF10A CT haplotype correlates with corticosteroid response in DMD patients and propose it as an exploratory CS response biomarker., The EU BIO-NMD project no. 241665 and the SOLVE-RD project (H2020 ID: 779257) were supported this study. FM was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. The support of the Muscular Dystrophy UK to the Dubowitz Neuromuscular Centre and of the MRC Neuromuscular Centre and BRC Biobank is also gratefully acknowledged. Part of this study was also supported by the NIHR grant “Rare Diseases Translational Research Collaboration” on Duchenne muscular dystrophy to FM. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). The EUROBIOBANK, European Network of DNA, Cell and Tissue Banks for Rare Diseases was also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Homozygous WASHC4 variant in two sisters causes a syndromic phenotype defined by dysmorphisms, intellectual disability, profound developmental disorder, and skeletal muscle involvement

  • Gangfuß, Andrea
  • Czech, Artur
  • Hentschel, Andreas
  • Münchberg, Ute
  • Horvath, Rita
  • Töpf, Ana
  • O'Heir, Emily
  • Lochmüller, Hanns
  • Stehling, Florian
  • Kiewert, Cordula
  • Sickmann, Albert
  • Kuechler, Alma
  • Kaiser, Frank J.
  • Kölbel, Heike
  • Christiansen, Jon
  • Schara-Schmidt, Ulrike
  • Roos, Andreas
Recessive variants in WASHC4 are linked to intellectual disability complicated by poor language skills, short stature, and dysmorphic features. The protein encoded by WASHC4 is part of the Wiskott-Aldrich syndrome protein and SCAR homolog family, co-localizes with actin in cells, and promotes Arp2/3-dependent actin polymerization in vitro. Functional studies in a zebrafish model suggested that WASHC4 knockdown may also affect skeletal muscles by perturbing protein clearance. However, skeletal muscle involvement has not been reported so far in patients, and precise biochemical studies allowing a deeper understanding of the molecular etiology of the disease are still lacking. Here, we report two siblings with a homozygous WASHC4 variant expanding the clinical spectrum of the disease and provide a phenotypical comparison with cases reported in the literature. Proteomic profiling of fibroblasts of the WASHC4-deficient patient revealed dysregulation of proteins relevant for the maintenance of the neuromuscular axis. Immunostaining on a muscle biopsy derived from the same patient confirmed dysregulation of proteins relevant for proper muscle function, thus highlighting an affliction of muscle cells upon loss of functional WASHC4. The results of histological and coherent anti-Stokes Raman scattering microscopic studies support the concept of a functional role of the WASHC4 protein in humans by altering protein processing and clearance. The proteomic analysis confirmed key molecular players in vitro and highlighted, for the first time, the involvement of skeletal muscle in patients. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland., This study was supported by four authors of this publication who are members of the European Reference Network for Neuromuscular Diseases – Project ID No 870177. This study was supported also by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin – Senatskanzlei Wissenschaft und Forschung’, and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz Research Cluster (grant number 031A360E). This work was also supported by a grant from the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR. RH was supported by the European Research Council (309548), a Wellcome Investigator Award (109915/Z/15/Z), the Medical Research Council (UK) (MR/N025431/1), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Parts of this study were financed within the framework of the NME-GPS project by the European Regional Development Fund (ERDF). AT is supported by the Horizon 2020 research and innovation program via grant 779257 ‘Solve-RD’. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solving unsolved rare neurological diseases-a Solve-RD viewpoint

  • Matalonga, Leslie
  • Timmann, Dagmar
  • Erasmus, Corrie E.
  • Reichbauer, Jennifer
  • Wayand, Melanie
  • Solve-RD-DITF-RND
  • van de Warrenburg, Bart
  • Schöls, Ludger
  • Wilke, Carlo
  • Bevot, Andrea
  • Zuchner, Stephan
  • Beltran, Sergi
  • Laurie, Steven, 1973-
  • Matalonga, Leslie
  • Graessner, Holm
  • Synofzik, Matthis
  • Solve-RD Consortium
Rare genetic neurological disorders (RND; ORPHA:71859) are a heterogeneous group of disorders comprising >1700 distinct genetic disease entities. However, genetic discoveries have not yet translated into dramatic increases of diagnostic yield and indeed rates of molecular genetic diagnoses have been stuck at about 30–50% across NGS modalities and RND phenotypes [1, 2]. Existence of yet unknown disease genes as well as shortcomings of commonly employed NGS technologies and analysis pipelines in detecting certain variant types are typically cited to explain the low diagnosis rates. To increase the diagnostic yield in RNDs - one of the four focus disease groups in Solve-RD - we follow two major approaches, that we will here present and exemplify: (i) systematic state-of the art re-analysis of large cohorts of unsolved whole-exome/genome sequencing (WES/WGS) RND datasets; and (ii) novel-omics approaches. Based on the way Solve-RD systematically organizes researchers’ expertise to channel this approach [3], the European Reference Network for Rare Neurological Diseases (ERN-RND) has established its own Data Interpretation Task Force (DITF) within SOLVE-RD, which is currently composed of clinical and genetic experts from 29 sites in 15 European countries., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 779257. Data were analysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (Grant Numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant Numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies. The study was further funded by the Federal Ministry of Education and Research, Germany, through the TreatHSP network (01GM1905 to RS and LS), the National Institute of Neurological Diseases and Stroke (R01NS072248 to SZ and RS), the European Joint Program on Rare Diseases-EJP-RD COFUND-EJP N° 825575 through funding for the PROSPAX consortium (441409627 to MS, RS and BvW). CW was supported by the PATE program of the Medical Faculty, University of Tübingen. CEE received support from the Dutch Princess Beatrix Muscle Fund and the Dutch Spieren voor Spieren Muscle fund. Authors on this paper are members of the European Reference Network for Rare Neurological Diseases (ERN-RND, Project ID 739510)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Standards of NGS data sharing and analysis in Ataxias: recommendations by the NGS Working Group of the Ataxia Global Initiative

  • Beijer, Danique
  • Fogel, Brent L.
  • Beltran, Sergi
  • Danzi, Matt C.
  • Németh, Andrea H.
  • Züchner, Stephan
  • Synofzik, Matthis
  • AGI Ataxia NGS genomics, platforms Working Group
The Ataxia Global Initiative (AGI) is a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias. The next-generation sequencing (NGS) working group of the AGI aims to improve methods, platforms, and international standards for ataxia NGS analysis and data sharing, ultimately allowing to increase the number of genetically ataxia patients amenable for natural history and treatment trials. Despite extensive implementation of NGS for ataxia patients in clinical and research settings, the diagnostic gap remains sizeable, as approximately 50% of patients with hereditary ataxia remain genetically undiagnosed. One current shortcoming is the fragmentation of patients and NGS datasets on different analysis platforms and databases around the world. The AGI NGS working group in collaboration with the AGI associated research platforms—CAGC, GENESIS, and RD-Connect GPAP—provides clinicians and scientists access to user-friendly and adaptable interfaces to analyze genome-scale patient data. These platforms also foster collaboration within the ataxia community. These efforts and tools have led to the diagnosis of > 500 ataxia patients and the discovery of > 30 novel ataxia genes. Here, the AGI NGS working group presents their consensus recommendations for NGS data sharing initiatives in the ataxia field, focusing on harmonized NGS variant analysis and standardized clinical and metadata collection, combined with collaborative data and analysis tool sharing across platforms., Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Horizon 2020 research and innovation programme (grant 779257 Solve-RD to MS and SB), and the European Joint Programme on Rare Diseases (grant 825575 EJP RD to SB) under the EJP RD COFUND-EJP No. 825575 (PROSPAX consortium, to MS and—as an associated partner—SZ). DB is supported by a Postdoctoral Fellowship from the Alexander von Humboldt Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources

  • Köhler, Sebastian
  • Beltran, Sergi
  • Lochmüller, Hanns
The Human Phenotype Ontology (HPO)-a standardized vocabulary of phenotypic abnormalities associated with 7000+ diseases-is used by thousands of researchers, clinicians, informaticians and electronic health record systems around the world. Its detailed descriptions of clinical abnormalities and computable disease definitions have made HPO the de facto standard for deep phenotyping in the field of rare disease. The HPO's interoperability with other ontologies has enabled it to be used to improve diagnostic accuracy by incorporating model organism data. It also plays a key role in the popular Exomiser tool, which identifies potential disease-causing variants from whole-exome or whole-genome sequencing data. Since the HPO was first introduced in 2008, its users have become both more numerous and more diverse. To meet these emerging needs, the project has added new content, language translations, mappings and computational tooling, as well as integrations with external community data. The HPO continues to collaborate with clinical adopters to improve specific areas of the ontology and extend standardized disease descriptions. The newly redesigned HPO website (www.human-phenotype-ontology.org) simplifies browsing terms and exploring clinical features, diseases, and human genes., National Institutes of Health (NIH), Monarch Initiative [OD #5R24OD011883]; Forums for Integrative Phenomics [U13 CA221044-01]; NCATS Data Translator [1OT3TR002019]; NCATS National Center for Digital Health Informatics Innovation [U24 TR002306]; NIH Data Commons [1 OT3 OD02464-01 UNCCH]; Cost Action CA 16118 Neuro-MIG; British Heart Foundation Programme Grant [RG/13/5/30112]; Division of Intramural Research; NIAID; NIH; E-RARE project Hipbi-RD [01GM1608]; European Union’s Horizon 2020 Research and Innovation Programme [779257]. Funding for open access charge: NIH; Donald A. Roux Family Fund (to P.N.R.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer

  • São José, Celina
  • Laurie, Steven, 1973-
  • Oliveira, Carla
Background: Germline CDH1 pathogenic or likely pathogenic variants cause hereditary diffuse gastric cancer (HDGC). Once a genetic cause is identified, stomachs' and breasts' surveillance and/or prophylactic surgery is offered to asymptomatic CDH1 carriers, which is life-saving. Herein, we characterized an inherited mechanism responsible for extremely early-onset gastric cancer and atypical HDGC high penetrance. Methods: Whole-exome sequencing (WES) re-analysis was performed in an unsolved HDGC family. Accessible chromatin and CDH1 promoter interactors were evaluated in normal stomach by ATAC-seq and 4C-seq, and functional analysis was performed using CRISPR-Cas9, RNA-seq and pathway analysis. Results: We identified a germline heterozygous 23 Kb CDH1-TANGO6 deletion in a family with eight diffuse gastric cancers, six before age 30. Atypical HDGC high penetrance and young cancer-onset argued towards a role for the deleted region downstream of CDH1, which we proved to present accessible chromatin, and CDH1 promoter interactors in normal stomach. CRISPR-Cas9 edited cells mimicking the CDH1-TANGO6 deletion display the strongest CDH1 mRNA downregulation, more impacted adhesion-associated, type-I interferon immune-associated and oncogenic signalling pathways, compared to wild-type or CDH1-deleted cells. This finding solved an 18-year family odyssey and engaged carrier family members in a cancer prevention pathway of care. Conclusion: In this work, we demonstrated that regulatory elements lying down-stream of CDH1 are part of a chromatin network that control CDH1 expression and influence cell transcriptome and associated signalling pathways, likely explaining high disease penetrance and very young cancer-onset. This study highlights the importance of incorporating scientific-technological updates and clinical guidelines in routine diagnosis, given their impact in timely genetic diagnosis and disease prevention., This work received funding from: (1) the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257 (Solve‐RD: H2020-SC1-2017-Single-Stage-RTD), which provided Ph.D. salaries to JG-P, AS, ItP; (2) The European Regional Development Fund (ERDF) through the COMPETE 2020-Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through Fundação para a Ciência e Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Inovação (LEGOH: PTDC/BTM-TEC/6706/2020); (3) FCT with salary support for Ph.D. studentships to CSJ (Ref. SFRH/BD/140796/2018), JG-P (Ref. 2022.11952.BD) and MF (Ref. 2020.05763.BD); (4) MT is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). Open access funding provided by FCT|FCCN (b-on).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases

  • Kurul, Semra Hiz
  • Matalonga, Leslie
  • Paramonov, Ida
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Lochmüller, Hanns
  • Horvath, Rita
Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families, recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two% of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families, and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialised bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity., The project is supported by TUBITAK (The Scientific and Technological Research Council of Turkey) Project No. 216S771. YO is supported by the Turkish Academy of Sciences’ Young Investigator award, TÜBA-GEBİP (2017). PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). RH was supported by the European Research Council [309548], the Wellcome Investigator Award [109915/Z/15/Z]. the Medical Research Council (UK) [MR/N025431/1]; the Wellcome Trust Pathfinder Scheme [201064/Z/16/Z], the Newton Fund [UK/Turkey, MR/N027302/1], the Lily Foundation and the Evelyn Trust. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. Data was analysed using the RD-Connect Genome-Phenome Analysis platform developed under FP7/2007-2013 funded project (grant agreement nº 305444) and funding from EJP-RD and INB/ELIXIR-ES. The study was further supported by the Horizon 2020 research and innovation program via grant 779257 “Solve-RD” (RH, SB, AT and HL). RH, PFC and YO were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1)

  • Töpf, Ana
  • Pyle, Angela
  • Griffin, Helen
  • Matalonga, Leslie
  • Schon, Katherine
  • Solve-RD SNV-indel working group
  • Solve-RD DITF-euroNMD
  • Sickmann, Albert
  • Schara-Schmidt, Ulrike
  • Hentschel, Andreas
  • Chinnery, Patrick F.
  • Kölbel, Heike
  • Roos, Andreas
TRIP4 is one of the subunits of the transcriptional coregulator ASC-1, a ribonucleoprotein complex that participates in transcriptional coactivation and RNA processing events. Recessive variants in the TRIP4 gene have been associated with spinal muscular atrophy with bone fractures as well as a severe form of congenital muscular dystrophy. Here we present the diagnostic journey of a patient with cerebellar hypoplasia and spinal muscular atrophy (PCH1) and congenital bone fractures. Initial exome sequencing analysis revealed no candidate variants. Reanalysis of the exome data by inclusion in the Solve-RD project resulted in the identification of a homozygous stop-gain variant in the TRIP4 gene, previously reported as disease-causing. This highlights the importance of analysis reiteration and improved and updated bioinformatic pipelines. Proteomic profile of the patient's fibroblasts showed altered RNA-processing and impaired exosome activity supporting the pathogenicity of the detected variant. In addition, we identified a novel genetic form of PCH1, further strengthening the link of this characteristic phenotype with altered RNA metabolism., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. Several authors of this study are members of the European Reference Network for Neuromuscular disease, Project ID No 739543. This study was supported by the AFM (grant 21644 to AR), the framework of the NME-GPS project by the European Regional Development Fund (AR/US/AS), the support by the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin-inkl. Wissenschaft und Forschung, and the Bundesministerium für Bildung und Forschung (AH and AS), the European Research Council (RH), the Wellcome Investigator Award (109915/Z/15/Z to RH), the Medical Research Council UK (MR/N025431/1 to RH), the Newton Fund (MR/N027302/1 to RH), the Lily Foundation (RH) and the Evelyn Trust (RH). This research was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1 and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation

  • Sušak, Hana, 1985-
  • Serra Saurina, Laura
  • Demidov, German, 1990-
  • Rabionet Janssen, Raquel
  • Domènech Salgado, Laura, 1989-
  • Bosio, Mattia
  • Muyas Remolar, Francesc, 1992-
  • Estivill, Xavier, 1955-
  • Escaramís, Geòrgia
  • Ossowski, Stephan
Rare variants are thought to play an important role in the etiology of complex diseases and may explain a significant fraction of the missing heritability in genetic disease studies. Next-generation sequencing facilitates the association of rare variants in coding or regulatory regions with complex diseases in large cohorts at genome-wide scale. However, rare variant association studies (RVAS) still lack power when cohorts are small to medium-sized and if genetic variation explains a small fraction of phenotypic variance. Here we present a novel Bayesian rare variant Association Test using Integrated Nested Laplace Approximation (BATI). Unlike existing RVAS tests, BATI allows integration of individual or variant-specific features as covariates, while efficiently performing inference based on full model estimation. We demonstrate that BATI outperforms established RVAS methods on realistic, semi-synthetic whole-exome sequencing cohorts, especially when using meaningful biological context, such as functional annotation. We show that BATI achieves power above 70% in scenarios in which competing tests fail to identify risk genes, e.g. when risk variants in sum explain less than 0.5% of phenotypic variance. We have integrated BATI, together with five existing RVAS tests in the 'Rare Variant Genome Wide Association Study' (rvGWAS) framework for data analyzed by whole-exome or whole genome sequencing. rvGWAS supports rare variant association for genes or any other biological unit such as promoters, while allowing the analysis of essential functionalities like quality control or filtering. Applying rvGWAS to a Chronic Lymphocytic Leukemia study we identified eight candidate predisposition genes, including EHMT2 and COPS7A., Funding: SO, HS, XE, FM and GD received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635290 (PanCanRisk). SO and GD received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257 (Solve-RD). RR received support from the Fundació La Marató 70/307:201726. HS, GD, RR, LD, MB, FM, XE, GE and SO received support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017, and the CERCA Programme / Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Wnt genes in colonic polyposis predisposition

  • Quintana, Isabel
  • Tonda, Raúl
  • Parra Farré, Genís
  • Piscia, Davide
  • Beltran, Sergi
  • Valle, Laura
This research was funded by the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), and co-funded by FEDER funds a way to build Europe [Grants No. SAF2016-80888-R (LV), PID2020-112595RB-I00 (LV), and PID2019-111254RB-I00 (GC), and predoctoral fellowship “Formación de Personal Investigador” (IQ)]; Instituto de Salud Carlos III [CIBERONC CB16/12/00234, Sara Borrell Postdoctoral contract (PM)]; Government of Catalonia, Spain [PERIS MedPerCan, AGAUR 2017SGR1282, CERCA Program for institutional support]; Scientific Foundation “Asociación Española Contra el Cáncer” [AECC Investigador (MT)]; Marie Skłodowska-Curie Individual Fellowship [Organ-VIP; Grant agreement No. 897064 (NG-A)]. The Solve-RD project is funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 779257. This study was supported by the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) - Project ID No. 739547 (www.genturis.eu), and the COST action CA17118, supported by COST (European Cooperation in Science and Technology).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Solve-RD ClinVar-based reanalysis of 1522 index cases from ERN-ITHACA reveals common pitfalls and misinterpretations in exome sequencing

  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Faivre, Laurence
Purpose: Within the Solve-RD project (https://solve-rd.eu/), the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies aimed to investigate whether a reanalysis of exomes from unsolved cases based on ClinVar annotations could establish additional diagnoses. We present the results of the "ClinVar low-hanging fruit" reanalysis, reasons for the failure of previous analyses, and lessons learned. Methods: Data from the first 3576 exomes (1522 probands and 2054 relatives) collected from European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies was reanalyzed by the Solve-RD consortium by evaluating for the presence of single-nucleotide variant, and small insertions and deletions already reported as (likely) pathogenic in ClinVar. Variants were filtered according to frequency, genotype, and mode of inheritance and reinterpreted. Results: We identified causal variants in 59 cases (3.9%), 50 of them also raised by other approaches and 9 leading to new diagnoses, highlighting interpretation challenges: variants in genes not known to be involved in human disease at the time of the first analysis, misleading genotypes, or variants undetected by local pipelines (variants in off-target regions, low quality filters, low allelic balance, or high frequency). Conclusion: The "ClinVar low-hanging fruit" analysis represents an effective, fast, and easy approach to recover causal variants from exome sequencing data, herewith contributing to the reduction of the diagnostic deadlock., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 779257. Data were analyzed using the RD-Connect Genome-Phenome Analysis Platform, which received funding from the EU projects RD-Connect, Solve-RD, and European Joint Programme on Rare Diseases (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática), and ELIXIR Implementation Studies. The collaborations in this study were facilitated by the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies, one of the 24 European Reference Networks approved by the European Reference Network Board of Member States, cofunded by the European Commission. This project was supported by the Czech Ministry of Health (number 00064203) and by the Czech Ministry of Education, Youth and Sports (number - LM2018132) to M.M.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases

  • Zurek, Birte
  • Laurie, Steven, 1973-
  • Beltran, Sergi
  • Solve-RD Consortium
For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient's data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together >300 clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs; ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of >19,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. This research is supported (not financially) by four ERNs: (1) The ERN for Intellectual Disability, Telehealth and Congenital Anomalies (ERN-ITHACA)—Project ID No 869189; (2) The ERN on Rare Neurological Diseases (ERN-RND)—Project ID No 739510; (3) The ERN for Neuromuscular Diseases (ERN Euro-NMD)—Project ID No 870177; (4) The ERN on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. The ERNs are co-funded by the European Union within the framework of the Third Health Programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GA4GH: International policies and standards for data sharing across genomic research and healthcare

  • Rehm, Heidi L.
  • Beltran, Sergi
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Palumbo, Emilio
  • Rambla de Argila, Jordi
  • Birney, Ewan
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits., B.P.C. acknowledges funding from Abigail Wexner Research Institute at Nationwide Children’s Hospital; T.H. Nyrönen acknowledges funding from Academy of Finland grant #31996; A.M.-J., K.N., T.F.B., O.M.H., and Z.S. acknowledge funding from Australian Medical Research Future Fund; M.S. acknowledges funding from Biobank Japan; D. Bujold and S.J.M.J. acknowledge funding from Canada Foundation for Innovation; L.J.D. acknowledges funding from Canada Foundation for Innovation Cyber Infrastructure grant #34860; D. Bujold and G.B. acknowledge funding from CANARIE; L.J.D. acknowledges funding from CANARIE Research Data Management contract #RDM-090 (CHORD) and #RDM2-053 (ClinDIG); K.K.-L. acknowledges funding from CanSHARE; T.L.T. acknowledges funding from Chan Zuckerberg Initiative; T. Burdett acknowledges funding from Chan Zuckerberg Initiative grant #2017-171671; D. Bujold, G.B., and L.D.S. acknowledge funding from CIHR; L.J.D. acknowledges funding from CIHR grant #404896; M.J.S.B. acknowledges funding from CIHR grant #SBD-163124; M. Courtot and M. Linden acknowledge funding from CINECA project EU Horizon 2020 grant #825775; D. Bujold and G.B. acknowledge funding from Compute Canada; F.M.-G. acknowledges funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – NFDI 1/1 “GHGA – German Human Genome-Phenome Archive; R.M.H.-S. acknowledges funding from Duke-Margolis Center for Health Policy; S.B. and A.J.B. acknowledge funding from EJP-RD EU Horizon 2020 grant #825575; A. Niewielska, A.K., D.S., G.I.S., J.A.T., J.R., M.A.K., M. Baudis, M. Linden, S.B., S.S., T.H. Nyrönen, and T.M.K. acknowledge funding from ELIXIR; A. Niewielska acknowledges funding from EOSC-Life EU Horizon 2020 grant #824087; J.-P.H. acknowledges funding from ETH Domain Strategic Focal Area “Personalized Health and Related Technologies (PHRT)” grant #2017-201; F.M.-G. acknowledges funding from EUCANCan EU Horizon 2020 grant #825835; B.M.K., D. Bujold, G.B., L.D.S., M.J.S.B., N.S., S.E.W., and Y.J. acknowledge funding from Genome Canada; B.M.K., M.J.S.B., S.E.W., and Y.J. acknowledge funding from Genome Quebec; F.M.-G. acknowledges funding from German Human Genome-Phenome Archive; C. Voisin acknowledges funding from Google; A.J.B. acknowledges funding from Health Data Research UK Substantive Site Award; D.H. acknowledges funding from Howard Hughes Medical Institute; S.B. acknowledges funding from Instituto de Salud Carlos III; S.-S.K. and K.T. acknowledge funding from Japan Agency for Medical Research and Development (AMED); S. Ogishima acknowledges funding from Japan Agency for Medical Research and Development (AMED) grant #20kk0205014h0005; C.Y. and K. Kosaki acknowledge funding from Japan Agency for Medical Research and Development (AMED) grant #JP18kk0205012; GEM Japan acknowledges funding from Japan Agency for Medical Research and Development (AMED) grants #19kk0205014h0004, #20kk0205014h0005, #20kk0205013h0005, #20kk0205012h0005, #20km0405401h0003, and #19km0405001h0104; J.R. acknowledges funding from La Caixa Foundation under project #LCF/PR/GN13/50260009; R.R.F. acknowledges funding from Mayo Clinic Center for Individualized Medicine; Y.J. and S.E.W. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE Connect Project; S.E.W. and S.O.M.D. acknowledge funding from Ministère de l’Économie et de l’Innovation du Québec for the Can-SHARE grant #141210; M.A.H., M.C.M.-T., J.O.J., H.E.P., and P.N.R. acknowledge funding from Monarch Initiative grant #R24OD011883 and Phenomics First NHGRI grant #1RM1HG010860; A.L.M. and E.B. acknowledge funding from MRC grant #MC_PC_19024; P.T. acknowledges funding from National University of Singapore and Agency for Science, Technology and Research; J.M.C. acknowledges funding from NHGRI; A.H.W. acknowledges funding from NHGRI awards K99HG010157, R00HG010157, and R35HG011949; A.M.-J., K.N., D.P.H., O.M.H., T.F.B., and Z.S. acknowledge funding from NHMRC grants #GNT1113531 and #GNT2000001; D.L.C. acknowledges funding from NHMRC Ideas grant #1188098; A.B.S. acknowledges funding from NHMRC Investigator Fellowship grant #APP177524; J.M.C. and L.D.S. acknowledge funding from NIH; A.A.P. acknowledges funding from NIH Anvil; A.V.S. acknowledges funding from NIH contract #HHSN268201800002I (TOPMed Informatics Research Center); S.U. acknowledges funding from NIH ENCODE grant #UM1HG009443; M.C.M.-T. and M.A.H. acknowledge funding from NIH grant #1U13CA221044; R.J.C. acknowledges funding from NIH grants #1U24HG010262 and #1U2COD023196; M.G. acknowledges funding from NIH grant #R00HG007940; J.B.A., S.L., P.G., E.B., H.L.R., and L.S. acknowledge funding from NIH grant #U24HG011025; K.P.E. acknowledges funding from NIH grant #U2C-RM-160010; J.A.E. acknowledges funding from NIH NCATS grant #U24TR002306; M.M. acknowledges funding from NIH NCI contract #HHSN261201400008c and ID/IQ Agreement #17X146 under contract #HHSN2612015000031 and #75N91019D00024; R.M.C.-D. acknowledges funding from NIH NCI grant #R01CA237118; M. Cline acknowledges funding from NIH NCI grant #U01CA242954; K.P.E. acknowledges funding from NIH NCI ITCR grant #1U24CA231877-01; O.L.G. acknowledges funding from NIH NCI ITCR grant #U24CA237719; R.L.G. acknowledges funding from NIH NCI task order #17X147F10 under contract #HHSN261200800001E; A.F.R. acknowledges funding from NIH NHGRI grant #RM1HG010461; N.M. and L.J.Z. acknowledge funding from NIH NHGRI grant #U24HG006941; R.R.F., T.H. Nelson, L.J.B., and H.L.R. acknowledge funding from NIH NHGRI grant #U41HG006834; B.J.W. acknowledges funding from NIH NHGRI grant #UM1HG009443A; M. Cline acknowledges funding from NIH NHLBI BioData Catalyst Fellowship grant #5118777; M.M. acknowledges funding from NIH NHLBI BioData Catalyst Program grant #1OT3HL142478-01; N.C.S. acknowledges funding from NIH NIGMS grant #R35-GM128636; M.C.M.-T., M.A.H., P.N.R., and R.R.F. acknowledge funding from NIH NLM contract #75N97019P00280; E.B. and A.L.M. acknowledge funding from NIHR; R.G. acknowledges funding from Project Ris3CAT VEIS; S.B. acknowledges funding from RD-Connect, Seventh Framework Program grant #305444; J.K. acknowledges funding from Robertson Foundation; S.B. and A.J.B. acknowledge funding from Solve-RD, EU Horizon 2020 grant #779257; T.S. and S. Oesterle acknowledge funding from Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN), supported by the Swiss State Secretariat for Education, Research and Innovation SERI; S.J.M.J. acknowledges funding from Terry Fox Research Institute; A.E.H., M.P.B., M. Cupak, M.F., and J.F. acknowledge funding from the Digital Technology Supercluster; D.F.V. acknowledges funding from the Australian Medical Research Future Fund, as part of the Genomics Health Futures Mission grant #76749; M. Baudis acknowledges funding from the BioMedIT Network project of Swiss Institute of Bioinformatics (SIB) and Swiss Personalized Health Network (SPHN); B.M.K. acknowledges funding from the Canada Research Chair in Law and Medicine and CIHR grant #SBD-163124; D.S., G.I.S., M.A.K., S.B., S.S., and T.H. Nyrönen acknowledge funding from the EU Horizon 2020 Beyond 1 Million Genomes (B1MG) Project grant #951724; P.F., A.D.Y., F.C., H.S., I.U.L., D. Gupta, M. Courtot, S.E.H., T. Burdett, T.M.K., and S.F. acknowledge funding from the European Molecular Biology Laboratory; Y.J. and S.E.W. acknowledge funding from the Government of Canada; P.G. acknowledges funding from the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-206); J.Z. acknowledges funding from the Government of Ontario; C.K.Y. acknowledges funding from the Government of Ontario, Canada Foundation for Innovation; C. Viner and M.M.H. acknowledge funding from the Natural Sciences and Engineering Research Council of Canada (grant #RGPIN-2015-03948 to M.M.H. and Alexander Graham Bell Canada Graduate Scholarship to C.V.); K.K.-L. acknowledges funding from the Program for Integrated Database of Clinical and Genomic Information; J.K. acknowledges funding from the Robertson Foundation; D.F.V. acknowledges funding from the Victorian State Government through the Operational Infrastructure Support (OIS) Program; A.M.L., R.N., and H.V.F. acknowledge funding from Wellcome (collaborative award); F.C., H.S., P.F., and S.E.H. acknowledge funding from Wellcome Trust grant #108749/Z/15/Z; A.D.Y., H.S., I.U.L., M. Courtot, H.E.P., P.F., and T.M.K. acknowledge funding from Wellcome Trust grant #201535/Z/16/Z; A.M., J.K.B., R.J.M., R.M.D., and T.M.K. acknowledge funding from Wellcome Trust grant #206194; E.B., P.F., P.G., and S.F. acknowledge funding from Wellcome Trust grant #220544/Z/20/Z; A. Hamosh acknowledges funding from NIH NHGRI grant U41HG006627 and U54HG006542; J.S.H. acknowledges funding from National Taiwan University #91F701-45C and #109T098-02; the work of K.W.R. was supported by the Intramural Research Program of the National Library of Medicine, NIH. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. H.V.F. acknowledges funding from Wellcome Grant 200990/A/16/Z ‘Designing, developing and delivering integrated foundations for genomic medicine'.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report

  • Te Paske, Iris B.A.W.
  • Garcia-Pelaez, José
  • Sommer, Anna K.
  • Matalonga, Leslie
  • Starzynska, Teresa
  • Jakubowska, Anna
  • Solve-RD-GENTURIS group
  • van der Post, Rachel S.
  • Lubinski, Jan
  • Oliveira, Carla
  • Hoogerbrugge, Nicoline
  • de Voer, Richarda M.
Hereditary diffuse gastric cancer (HDGC) is associated with germline deleterious variants in CDH1 and CTNNA1. The majority of HDGC-suspected patients are still genetically unresolved, raising the need for identification of novel HDGC predisposing genes. Under the collaborative environment of the SOLVE-RD consortium, re-analysis of whole-exome sequencing data from unresolved gastric cancer cases (n = 83) identified a mosaic missense variant in PIK3CA in a 25-year-old female with diffuse gastric cancer (DGC) without familial history for cancer. The variant, c.3140A>G p.(His1047Arg), a known cancer-related somatic hotspot, was present at a low variant allele frequency (18%) in leukocyte-derived DNA. Somatic variants in PIK3CA are usually associated with overgrowth, a phenotype that was not observed in this patient. This report highlights mosaicism as a potential, and understudied, mechanism in the etiology of DGC., The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257. The research work at i3S/Ipatimup is supported by the European Regional Development Fund (ERDF) through COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT/ Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and Project Ref. POCI-01-0145-FEDER-030164. Data was reanalysed using the RD‐Connect Genome‐Phenome Analysis Platform, which received funding from EU projects RD‐Connect, Solve-RD and EJP-RD (grant numbers FP7 305444, H2020 779257, H2020 825575), Instituto de Salud Carlos III (grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB) and ELIXIR Implementation Studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mobile element insertions in rare diseases: a comparative benchmark and reanalysis of 60,000 exome samples

  • Wijngaard, Robin
  • Laurie, Steven, 1973-
  • Gilissen, Christian
Mobile element insertions (MEIs) are a known cause of genetic disease but have been underexplored due to technical limitations of genetic testing methods. Various bioinformatic tools have been developed to identify MEIs in Next Generation Sequencing data. However, most tools have been developed specifically for genome sequencing (GS) data rather than exome sequencing (ES) data, which remains more widely used for routine diagnostic testing. In this study, we benchmarked six MEI detection tools (ERVcaller, MELT, Mobster, SCRAMble, TEMP2 and xTea) on ES data and on GS data from publicly available genomic samples (HG002, NA12878). For all the tools we evaluated sensitivity and precision of different filtering strategies. Results show that there were substantial differences in tool performance between ES and GS data. MELT performed best with ES data and its combination with SCRAMble increased substantially the detection rate of MEIs. By applying both tools to 10,890 ES samples from Solve-RD and 52,624 samples from Radboudumc we were able to diagnose 10 patients who had remained undiagnosed by conventional ES analysis until now. Our study shows that MELT and SCRAMble can be used reliably to identify clinically relevant MEIs in ES data. This may lead to an additional diagnosis for 1 in 3000 to 4000 patients in routine clinical ES., Funding The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 779257. RW received an international fellowship from the José Luis Castaño-SEQC Foundation. FM is supported by the Edmond J. Safra Foundation through the Edmond J. Safra Fellowship in Movement Disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-wide variant calling in reanalysis of exome sequencing data uncovered a pathogenic TUBB3 variant

  • Boer, Elke de
  • Yaldiz, Burcu
  • Denommé-Pichon, Anne-Sophie
  • Matalonga, Leslie
  • Laurie, Steven, 1973-
  • Solve-RD SNV-indel working group
  • Solve-RD-DITF-ITHACA
Almost half of all individuals affected by intellectual disability (ID) remain undiagnosed. In the Solve-RD project, exome sequencing (ES) datasets from unresolved individuals with (syndromic) ID (n = 1,472 probands) are systematically reanalyzed, starting from raw sequencing files, followed by genome-wide variant calling and new data interpretation. This strategy led to the identification of a disease-causing de novo missense variant in TUBB3 in a girl with severe developmental delay, secondary microcephaly, brain imaging abnormalities, high hypermetropia, strabismus and short stature. Interestingly, the TUBB3 variant could only be identified through reanalysis of ES data using a genome-wide variant calling approach, despite being located in protein coding sequence. More detailed analysis revealed that the position of the variant within exon 5 of TUBB3 was not targeted by the enrichment kit, although consistent high-quality coverage was obtained at this position, resulting from nearby targets that provide off-target coverage. In the initial analysis, variant calling was restricted to the exon targets ± 200 bases, allowing the variant to escape detection by the variant calling algorithm. This phenomenon may potentially occur more often, as we determined that 36 established ID genes have robust off-target coverage in coding sequence. Moreover, within these regions, for 17 genes (likely) pathogenic variants have been identified before. Therefore, this clinical report highlights that, although compute-intensive, performing genome-wide variant calling instead of target-based calling may lead to the detection of diagnostically relevant variants that would otherwise remain unnoticed., This work was financially supported by Aspasia grants of the Dutch Research Council (015.014.036 to TK and 015.014.066 to LELMV) and Netherlands Organization for Health Research and Development (917.183.10 to TK). The Solve-RD project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779257.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia

  • Masson, Aymeric
  • Pérez Jurado, Luis Alberto
  • Sevilla-Porras, Marta
  • Vitobello, Antonio
Polypyrimidine tract-binding protein 1 (PTBP1) is a heterogeneous nuclear ribonucleoprotein primarily known for its alternative splicing activity. It shuttles between the nucleus and cytoplasm via partially overlapping N-terminal nuclear localization (NLS) and export (NES) signals. Despite its fundamental role in cell growth and differentiation, its involvement in human disease remains poorly understood. We identified 27 individuals from 25 families harboring de novo or inherited pathogenic variants - predominantly start-loss (89%) and, to a lesser extent, missense (11%) - affecting NES/NLS motifs. Affected individuals presented with a syndromic neurodevelopmental disorder and variable skeletal dysplasia with disproportionate short stature with short limbs. Intellectual functioning ranged from normal to moderately delayed. Start-loss variants led to translation initiation from an alternative downstream in-frame methionine, resulting in loss of the NES and the first half of the bipartite NLS, and increased cytoplasmic stability. Start-loss and missense variants shared a DNA methylation episignature in peripheral blood and altered nucleocytoplasmic distribution in vitro and in vivo with preferential accumulation in processing bodies, causing aberrant gene expression but normal RNA splicing. Transcriptomic analysis of patient-derived fibroblasts revealed dysregulated pathways involved in osteochondrogenesis and neurodevelopment. Overall, our findings highlight a cytoplasmic role for PTBP1 in RNA stability and disease pathogenesis., European Union's Horizon 2020 research and innovation program grant agreement number 779257.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeted therapies for metabolic myopathies related to glycogen storage and lipid metabolism: a systematic review and steps towards a 'Treatabolome'

  • Manta, Alexander
  • Spendiff, Sally
  • Lochmüller, Hanns
  • Thompson, Rachel
Background: Metabolic myopathies are a heterogenous group of muscle diseases typically characterized by exercise intolerance, myalgia and progressive muscle weakness. Effective treatments for some of these diseases are available, but while our understanding of the pathogenesis of metabolic myopathies related to glycogen storage, lipid metabolism and β-oxidation is well established, evidence linking treatments with the precise causative genetic defect is lacking. Objective: The objective of this study was to collate all published evidence on pharmacological therapies for the aforementioned metabolic myopathies and link this to the genetic mutation in a format amenable to databasing for further computational use in line with the principles of the "treatabolome" project. Methods: A systematic literature review was conducted to retrieve all levels of evidence examining the therapeutic efficacy of pharmacological treatments on metabolic myopathies related to glycogen storage and lipid metabolism. A key inclusion criterion was the availability of the genetic variant of the treated patients in order to link treatment outcome with the genetic defect. Results: Of the 1,085 articles initially identified, 268 full-text articles were assessed for eligibility, of which 87 were carried over into the final data extraction. The most studied metabolic myopathies were Pompe disease (45 articles), multiple acyl-CoA dehydrogenase deficiency related to mutations in the ETFDH gene (15 articles) and systemic primary carnitine deficiency (8 articles). The most studied therapeutic management strategies for these diseases were enzyme replacement therapy, riboflavin, and carnitine supplementation, respectively. Conclusions: This systematic review provides evidence for treatments of metabolic myopathies linked with the genetic defect in a computationally accessible format suitable for databasing in the treatabolome system, which will enable clinicians to acquire evidence on appropriate therapeutic options for their patient at the time of diagnosis., AM received a Summer Studentship stipend from the Faculty of Medicine at the University of Ottawa. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant NG2-170044 for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). RT receives support from the Canadian Institutes of Health Research (postdoctoral fellowship award MFE-171275). This review is part of the Solve-RD treatabolome initiative. The Solve-RD project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779257
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Systematic collaborative reanalysis of genomic data improves diagnostic yield in neurologic rare diseases

  • Bullich, Gemma
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • González, Juan Ramón
  • Laurie, Steven, 1973-
  • Luengo, Cristina
  • Ovelleiro, David
  • Parra Farré, Genís
  • Pérez Jurado, Luis Alberto
  • Beltran, Sergi
  • Undiagnosed Rare Disease Program of Catalonia (URD-Cat) Consortium
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%)., Supported by Generalitat de Catalunya through Departament de Salut (SLT002/16/00174 to URD-Cat consortium) and Departament d’Empresa i Coneixement and the CERCA Program; FP7 and H2020 EU projects RD-Connect, Solve-RD, and EJP-RD grants FP7 305444, H2020 779257, and H2020 825575 for CNAG-CRG; Spanish Ministry of Science and Innovation to the EMBL partnership and through the Instituto de Salud Carlos III grants PT13/0001/0044 and PT17/0009/0019 for CNAG-CRG and grants PI16/01048, PI19/01310, PI18/00451, PI18/00498, and PI21/00935 for IDIBAPS (Instituto Nacional de Bioinformática); ELIXIR Implementation Studies (CNAG-CRG); Centro de Investigaciones Biomédicas en Red de Enfermedades Raras; Centro de Excelencia Severo Ochoa grant SEV-2016-0571 (CNAG-CRG) and grant CEX 2018-000806-S (ISGLOBAL); and cofinancing with funds from the European Regional Development Fund by the Spanish Ministry of Science and Innovation corresponding to the Programa Operativo FEDER Plurirregional de España (POPE) 2014 to 2020 and by the Secretaria d’Universitats i Recerca, Departament d’Empresa i Coneixement of the Generalitat de Catalunya corresponding to the Programa Operatiu FEDER de Catalunya 2014 to 2020.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation

  • Susak, Hana
  • Serra-Saurina, Laura
  • Demidov, German
  • Rabionet Janssen, Raquel
  • Domènech, Laura
  • Bosio, Mattia
  • Muyas, Francesc
  • Estivill, Xavier, 1955-
  • Escaramís Babiano, Geòrgia
  • Ossowski, Stephan
Rare variants are thought to play an important role in the etiology of complex diseases and may explain a significant fraction of the missing heritability in genetic disease studies. Next-generation sequencing facilitates the association of rare variants in coding or regulatory regions with complex diseases in large cohorts at genome-wide scale. However, rare variant association studies (RVAS) still lack power when cohorts are small to medium-sized and if genetic variation explains a small fraction of phenotypic variance. Here we present a novel Bayesian rare variant Association Test using Integrated Nested Laplace Approximation (BATI). Unlike existing RVAS tests, BATI allows integration of individual or variant-specific features as covariates, while efficiently performing inference based on full model estimation. We demonstrate that BATI outperforms established RVAS methods on realistic, semi-synthetic whole-exome sequencing cohorts, especially when using meaningful biological context, such as functional annotation. We show that BATI achieves power above 70% in scenarios in which competing tests fail to identify risk genes, e.g. when risk variants in sum explain less than 0.5% of phenotypic variance. We have integrated BATI, together with five existing RVAS tests in the 'Rare Variant Genome Wide Association Study' (rvGWAS) framework for data analyzed by whole-exome or whole genome sequencing. rvGWAS supports rare variant association for genes or any other biological unit such as promoters, while allowing the analysis of essential functionalities like quality control or filtering. Applying rvGWAS to a Chronic Lymphocytic Leukemia study we identified eight candidate predisposition genes, including EHMT2 and COPS7A.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D'Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

  • Salpietro, Vincenzo
  • Dixon, Christine L.
  • Guo, Hui
  • Bello, Oscar D.|||0000-0001-5701-8365
  • Vandrovcova, Jana
  • Efthymiou, Stephanie|||0000-0003-4900-9877
  • Maroofian, Reza
  • Heimer, Gali
  • Burglen, Lydie|||0000-0002-1119-6809
  • Valence, Stephanie|||0000-0003-4530-4537
  • Torti, Erin|||0000-0001-5790-1051
  • Hacke, Moritz
  • Rankin, Julia
  • Tariq, Huma|||0000-0002-4351-0241
  • Colin, Estelle
  • Procaccio, Vincent
  • Striano, Pasquale|||0000-0002-6065-1476
  • Mankad, Kshitij
  • Lieb, Andreas|||0000-0001-9567-649X
  • Chen, Sharon
  • Pisani, Laura
  • Bettencourt, Conceição|||0000-0001-9090-7690
  • Männikkö, Roope|||0000-0002-8727-9184
  • Manole, Andreea
  • Brusco, Alfredo|||0000-0002-8318-7231
  • Grosso, Enrico
  • Ferrero, Giovanni Battista|||0000-0002-3793-5788
  • Armstrong, Judith|||0000-0003-0588-9307
  • Gueden, Sophie
  • Bar-Yosef, Omer
  • Tzadok, Michal
  • Monaghan, Kristin G.
  • Santiago-Sim, Teresa
  • Person, Richard E.
  • Cho, Megan T.
  • Willaert, Rebecca
  • Yoo, Kristin
  • Chae, Jong-Hee
  • Quan, Yingting
  • Wu, Huidan
  • Wang, Tianyun
  • Bernier, Raphael A.
  • Xia, Kun
  • Blesson, Alyssa
  • Jain, Mahim
  • Motazacker, Mohammad M.
  • Jaeger, Bregje
  • Schneider, Amy L.|||0000-0001-5260-7187
  • Boysen, Katja|||0000-0002-4444-2797
  • Muir, Alison M.|||0000-0002-9420-085X
  • Myers, Candance T.
  • Gavrilova, Ralitza H.
  • Gunderson, Lauren
  • Schultz-Rogers, Laura|||0000-0002-7222-9985
  • Klee, Eric W.
  • Dyment, David
  • Osmond, Matthew
  • Parellada, Mara|||0000-0001-7977-3601
  • Llorente, Cloe
  • González-Peñas, Javier|||0000-0002-3850-3012
  • Carracedo, Ángel|||0000-0003-1085-8986
  • van Haeringen, Arie
  • Ruivenkamp, Claudia A.L.
  • Nava, Caroline|||0000-0003-1272-0518
  • Heron, Delphine
  • Nardello, Rosaria
  • Iacomino, Michele|||0000-0003-4788-9719
  • Minetti, Carlo|||0000-0002-0640-1804
  • Skabar, Aldo|||0000-0003-3034-8203
  • Fabretto, Antonella
  • Hanna, Michael|||0000-0003-0825-4075
  • Bugiardini, Enrico|||0000-0002-9709-6699
  • Hostettler, Isabel Charlotte|||0000-0002-9004-2540
  • O'Callaghan, Benjamin
  • Khan, Alaa
  • Cortese, Andrea
  • O'Connor, Emer
  • Yau, Wai Y.
  • Bourinaris, Thomas
  • Kaiyrzhanov, Rauan|||0000-0003-1640-4010
  • Chelban, Viorica|||0000-0002-5817-6290
  • Madej, Monika
  • Diana, Maria C.
  • Vari, Maria S.
  • Pedemonte, Marina|||0000-0001-8410-6918
  • Bruno, Claudio
  • Balagura, Ganna|||0000-0003-0212-8318
  • Scala, Marcello|||0000-0003-2194-7239
  • Fiorillo, Chiara|||0000-0001-9027-343X
  • Nobili, Lino|||0000-0001-9317-5405
  • Malintan, Nancy T.
  • Zanetti, Maria N.|||0000-0002-3992-7167
  • Krishnakumar, Shyam S.
  • Lignani, Gabriele|||0000-0002-3963-9296
  • Jepson, James E. C.
  • Broda, Paolo|||0000-0002-4178-1128
  • Baldassari, Simona|||0000-0002-5304-3608
  • Rossi, Pia
  • Fruscione, Floriana|||0000-0002-4054-645X
  • Madia, Francesca|||0000-0002-7807-1322
  • Traverso, Monica|||0000-0003-0606-8797
  • De-Marco, Patrizia|||0000-0001-8498-3750
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Kriouile, Yamna
  • El-Khorassani, Mohamed
  • Karashova, Blagovesta
  • Avdjieva, Daniela
  • Kathom, Hadil
  • Tincheva, Radka
  • Van-Maldergem, Lionel|||0000-0001-8880-5214
  • Nachbauer, Wolfgang
  • Boesch, Sylvia|||0000-0003-1657-7368
  • Gagliano, Antonella
  • Amadori, Elisabetta
  • Goraya, Jatinder S.
  • Sultan, Tipu
  • Kirmani, Salman
  • Ibrahim, Shahnaz
  • Jan, Farida
  • Mine, Jun
  • Banu, Selina
  • Veggiotti, Pierangelo|||0000-0003-2851-3441
  • Zuccotti, Gian V.
  • Ferrari, Michel D.|||0000-0001-9691-9449
  • Van Den Maagdenberg, Arn M. J.
  • Verrotti, Alberto
  • Marseglia, Gian Luigi|||0000-0003-3662-0159
  • Savasta, Salvatore
  • Soler, Miguel A.|||0000-0002-5780-9949
  • Scuderi, Carmela|||0000-0001-5901-0041
  • Borgione, Eugenia|||0000-0001-5458-7415
  • Chimenz, Roberto
  • Gitto, Eloisa|||0000-0001-7442-8630
  • Dipasquale, Valeria|||0000-0003-3328-0734
  • Sallemi, Alessia
  • Fusco, Monica
  • Cuppari, Caterina
  • Cutrupi, Maria C.
  • Ruggieri, Martino
  • Cama, Armando
  • Capra, Valeria|||0000-0002-3097-0388
  • Mencacci, Niccolò Emanuele|||0000-0003-3383-9665
  • Boles, Richard
  • Gupta, Neerja
  • Kabra, Madhulika
  • Papacostas, Savvas|||0000-0003-3845-7439
  • Zamba-Papanicolaou, Eleni
  • Dardiotis, Efthimios|||0000-0003-2957-641X
  • Maqbool, Shazia
  • Rana, Nuzhat
  • Atawneh, Osama
  • Lim, Shen Y.
  • Shaikh, Mohmad Farooq|||0000-0001-9865-6224
  • Koutsis, George|||0000-0002-8980-8377
  • Breza, Marianthi|||0000-0001-9213-7941
  • Coviello, Domenico|||0000-0001-8440-865X
  • Dauvilliers, Yves|||0000-0003-0683-6506
  • AlKhawaja, Issam
  • AlKhawaja, Mariam
  • Al-Mutairi, Fuad
  • Stojkovic, Tanya|||0000-0002-4054-2838
  • Ferrucci, Veronica|||0000-0002-2019-6501
  • Zollo, Massimo|||0000-0002-0970-7243
  • Alkuraya, Fowzan S.|||0000-0003-4158-341X
  • Kinali, Maria
  • Sherifa, Hamed
  • Benrhouma, Hanene
  • Turki, Ilhem B. Y.
  • Tazir, Meriem
  • Obeid, Makram|||0000-0003-4349-674X
  • Bakhtadze, Sophia|||0000-0003-4862-4026
  • Saadi, Marianthi W.
  • Zaki, Maha|||0000-0001-7840-0002
  • Triki, Chahnez C.
  • Benfenati, Fabio
  • Gustincich, Stefano|||0000-0002-2749-2514
  • Kara, Majdi
  • Belcastro, Vincenzo
  • Specchio, Nicola|||0000-0002-8120-0287
  • Capovilla, Giuseppe
  • Karimiani, Ehsan G.
  • Salih, Ahmed M.
  • Okubadejo, Njideka|||0000-0003-2975-8803
  • Ojo, Oluwadamilola|||0000-0001-6461-2653
  • Oshinaike, Olajumoke O.
  • Oguntunde, Olapeju
  • Wahab, Kolawole Wasiu|||0000-0002-2914-1953
  • Bello, Abiodun H.
  • Abubakar, Sanni
  • Obiabo, Yahaya
  • Nwazor, Ernest
  • Ekenze, Oluchi
  • Williams, Uduak|||0000-0001-7120-2572
  • Iyagba, Alagoma
  • Taiwo, Lolade
  • Komolafe, Morenikeji|||0000-0002-0592-5120
  • Senkevich, Konstantin|||0000-0003-3407-5716
  • Shashkin, Chingiz
  • Zharkynbekova, Nazira
  • Koneyev, Kairgali
  • Manizha, Ganieva
  • Isrofilov, Maksud
  • Guliyeva, Ulviyya|||0000-0003-3834-336X
  • Salayev, Kamran
  • Khachatryan, Samson G.|||0000-0002-3098-2135
  • Rossi, Salvatore|||0000-0002-7102-9180
  • Silvestri, Gabriella|||0000-0002-1950-1468
  • Haridy, Nourelhoda A.|||0000-0001-6045-3309
  • Ramenghi, Luca A.|||0000-0003-0065-762X
  • Xiromerisiou, Georgia|||0000-0001-7162-3588
  • David, Emanuele
  • Aguennouz, M'hammed|||0000-0003-0440-0354
  • Fidani, Lliana
  • Spanaki, Cleanthe
  • Tucci, Arianna|||0000-0001-5644-0070
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Chez, Michael
  • Tsai, Anne
  • Fassi, Emily
  • Shinawi, Marwan|||0000-0003-1329-4100
  • Constantino, John N.
  • De Zorzi, Rita|||0000-0001-7001-7498
  • Fortuna, Sara|||0000-0002-8059-6064
  • Kok, Fernando
  • Keren, Boris
  • Bonneau, Dominique
  • Choi, Murim|||0000-0002-9195-1455
  • Benzeev, Bruria
  • Zara, Federico|||0000-0001-9744-5222
  • Mefford, Heather C.|||0000-0001-7188-522X
  • Scheffer, Ingrid E.
  • Clayton-Smith, Jill
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Rothman, James E.
  • Eichler, Evan E.|||0000-0002-8246-4014
  • Kullmann, Dimitri M.|||0000-0001-6696-3545
  • Houlden, Henry|||0000-0002-2866-7777
AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric AMPARs Ca-impermeable, with a linear relationship between current and trans-membrane voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonist-evoked current mediated by mutant subunits compared to wild-type channels. When GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased current amplitude and some also affect voltage rectification. Our results show that de-novo variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19

  • Solanich, Xavier|||0000-0002-2572-2187
  • Vargas-Parra, Gardenia|||0000-0003-1378-736X
  • Van der Made, Caspar I oud
  • Schuurs-Hoeijmakers, Janneke
  • Antolí, Arnau
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Rocamora-Blanch, Gemma
  • Setién, Fernando
  • Esteller, M.|||0000-0003-4490-6093
  • Van Reijmersdal, Simon V.
  • Riera Mestre, Antoni|||0000-0001-9411-804X
  • Sabater-Riera, Joan|||0000-0003-1246-5537
  • Capella, Gabriel|||0000-0002-4669-7320
  • Van de Veerdonk, Frank L v
  • Van der Hoven, Ben
  • Corbella, Xavier|||0000-0001-9889-0272
  • Hoischen, Alexander
  • Lázaro García, Conxi|||0000-0002-7198-5906
Introduction: Loss-of-function TLR7 variants have been recently reported in a small number of males to underlie strong predisposition to severe COVID-19. We aimed to determine the presence of these rare variants in young men with severe COVID-19. Methods: We prospectively studied males between 18 and 50 years-old without predisposing comorbidities that required at least high-flow nasal oxygen to treat COVID-19. The coding region of TLR7 was sequenced to assess the presence of potentially deleterious variants. Results: TLR7 missense variants were identified in two out of 14 patients (14.3%). Overall, the median age was 38 (IQR 30-45) years. Both variants were not previously reported in population control databases and were predicted to be damaging by in silico predictors. In a 30-year-old patient a maternally inherited variant [c.644A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Systematic Collaborative Reanalysis of Genomic Data Improves Diagnostic Yield in Neurologic Rare Diseases

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Matalonga, Leslie
  • Pujadas, Montserrat
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Tonda, Raúl
  • Artuch, R.|||0000-0002-3422-9685
  • Gallano, Pia|||0000-0001-8104-2197
  • Garrabou, Glòria|||0000-0001-8973-9933
  • González, Juan R.|||0000-0003-3267-2146
  • Grinberg, Daniel|||0000-0001-9859-2590
  • Guitart, Maria|||0000-0003-2957-7404
  • Laurie, Steven|||0000-0003-3913-5829
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Luengo, Cristina
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Milà, Montserrat
  • Ovelleiro, David|||0000-0002-9415-2229
  • Parra, Genís
  • Pujol, Aurora|||0000-0002-9606-0600
  • Tizzano, Eduardo F.|||0000-0002-7116-6310
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Palau, Francesc|||0000-0002-8635-5421
  • Ribes, Antònia
  • Pérez-Jurado, Luis Alberto|||0000-0002-1988-3005
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Schlüter, Agatha|||0000-0001-6732-1528
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Cáceres, Alejandro|||0000-0001-8551-6695
  • Nascimento, Andrés
  • García-Cazorla, Àngels
  • Cueto-González, Anna Mª|||0000-0001-7694-6124
  • Marcé-Grau, Anna|||0000-0001-5762-4023
  • Ruiz Nel Lo, Anna
  • Martínez-Monseny, Antonio
  • Sánchez, Aurora|||0000-0003-1167-1451
  • García, Belén
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Gel, Bernat|||0000-0001-8878-349X
  • Fusté, Berta
  • Hernández Ferrer, Carles
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Arjona, César
  • Hernando Davalillo, Cristina
  • Natera de Benito, Daniel
  • Picó Amador, Daniel
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Yubero, Délia
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • Verdura, Edgard|||0000-0003-3856-2060
  • García Arumí, Elena|||0000-0003-1848-005X
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • Gabau, Elisabeth|||0000-0001-8120-7393
  • Tobías, Ester|||0000-0002-9968-3651
  • López-Grondona, Fermina
  • Cardellach, Francesc|||0000-0003-3286-3436
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Tort, Frederic|||0000-0003-2733-1603
  • Aznar, Gemma
  • Olive Cirera, Gemma
  • Tell-Martí, Gemma|||0000-0003-2728-6961
  • Muñoz-Pujol, Gerard|||0000-0002-6863-3993
  • Paramonov, Ida
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Madrigal, Irene|||0000-0002-7229-1199
  • Valenzuela, Irene|||0000-0003-2350-6058
  • Gut, Ivo|||0000-0001-7219-632X
  • Cusco, Ivon|||0000-0003-2104-9332
  • Trotta, Jean-Rémi
  • Cruz, Jordi
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Milisenda, José César|||0000-0003-0151-7872
  • Ma Grau, Josep
  • Garcia-Villoria, Judit
  • Armstrong, Judith|||0000-0003-0588-9307
  • Cantó, Judith
  • Sala-Coromina, Júlia|||0000-0001-5116-6316
  • Rodríguez-Revenga, Laia
  • Alías, Laura|||0000-0003-2193-6185
  • Gort, Laura|||0000-0003-4746-1034
  • González Quereda, Lidia|||0000-0003-0715-6414
  • Costa, Mar
  • Fernández-Callejo, Marcos
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Gut, Marta|||0000-0002-4063-7159
  • Serrano, Mercedes|||0000-0002-2056-2428
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Bayés, Mònica
  • Baena Díez, Neus|||0000-0003-0677-240X
  • Spataro, Nino|||0000-0002-2127-2238
  • Capdevila, Núria|||0000-0003-2080-7381
  • Ugarteburu, Olatz|||0000-0003-4214-3301
  • Muñoz-Cabello, Patricia|||0000-0002-5242-9605
  • Romero Duque, Penélope|||0000-0003-3509-1320
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Calvo-Escalona, Rosa|||0000-0001-9572-4228
  • Urreizti, Roser|||0000-0003-3617-7134
  • Bernal, Sara|||0000-0003-4427-0574
  • Boronat Guerrero, Susana|||0000-0001-7096-5578
  • Balcells, Susana|||0000-0003-1211-1907
  • Vendrell, Teresa
Many patients experiencing a rare disease remain undiagnosed even after genomic testing. Reanalysis of existing genomic data has shown to increase diagnostic yield, although there are few systematic and comprehensive reanalysis efforts that enable collaborative interpretation and future reinterpretation. The Undiagnosed Rare Disease Program of Catalonia project collated previously inconclusive good quality genomic data (panels, exomes, and genomes) and standardized phenotypic profiles from 323 families (543 individuals) with a neurologic rare disease. The data were reanalyzed systematically to identify relatedness, runs of homozygosity, consanguinity, single-nucleotide variants, insertions and deletions, and copy number variants. Data were shared and collaboratively interpreted within the consortium through a customized Genome-Phenome Analysis Platform, which also enables future data reinterpretation. Reanalysis of existing genomic data provided a diagnosis for 20.7% of the patients, including 1.8% diagnosed after the generation of additional genomic data to identify a second pathogenic heterozygous variant. Diagnostic rate was significantly higher for family-based exome/genome reanalysis compared with singleton panels. Most new diagnoses were attributable to recent gene-disease associations (50.8%), additional or improved bioinformatic analysis (19.7%), and standardized phenotyping data integrated within the Undiagnosed Rare Disease Program of Catalonia Genome-Phenome Analysis Platform functionalities (18%).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Integrated Transcriptomics and Genomics Approach Detects an X/Autosome Translocation in a Female with Duchenne Muscular Dystrophy

  • Segarra Casas, Alba|||0000-0001-5185-5031
  • Yépez, Vicente A.|||0000-0001-7916-3643
  • Demidov, German|||0000-0001-9075-4276
  • Laurie, Steven|||0000-0003-3913-5829
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Gagneur, Julien|||0000-0002-8924-8365
  • Parkhurst, Yolande
  • Muni-Lofra, Robert|||0000-0002-8901-9140
  • Harris, Elizabeth
  • Marini-Bettolo, Chiara|||0000-0003-3795-6017
  • Straub, Volker|||0000-0001-9046-3540
  • Töpf, Ana
Duchenne and Becker muscular dystrophies, caused by pathogenic variants in DMD, are the most common inherited neuromuscular conditions in childhood. These diseases follow an X-linked recessive inheritance pattern, and mainly males are affected. The most prevalent pathogenic variants in the DMD gene are copy number variants (CNVs), and most patients achieve their genetic diagnosis through Multiplex Ligation-dependent Probe Amplification (MLPA) or exome sequencing. Here, we investigated a female patient presenting with muscular dystrophy who remained genetically undiagnosed after MLPA and exome sequencing. RNA sequencing (RNAseq) from the patient's muscle biopsy identified an 85% reduction in DMD expression compared to 116 muscle samples included in the cohort. A de novo balanced translocation between chromosome 17 and the X chromosome (t(X;17)(p21.1;q23.2)) disrupting the DMD and BCAS3 genes was identified through trio whole genome sequencing (WGS). The combined analysis of RNAseq and WGS played a crucial role in the detection and characterisation of the disease-causing variant in this patient, who had been undiagnosed for over two decades. This case illustrates the diagnostic odyssey of female DMD patients with complex structural variants that are not detected by current panel or exome sequencing analysis.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Alternative splicing expands the clinical spectrum of ndufs6-related mitochondrial disorders

  • Armirola Ricaurte, C.
  • Zonnekein, N.
  • Koutsis, G.
  • Morís de la Tassa, Germán|||0000-0001-7608-2194
The European Community’s Seventh Framework Programme (FP7/ 2007-2013) under grant agreement n◦ 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and CMMC (C18) to B.W., a CMMC clinical scientist award to M.K., the Carlos III Health Institute (ISCIII) (Grant PI21/00103 to C.E.), the European Union—European Regional Development Fund and the European Social Fund (FSE) “A way of making Europe.” This research was funded in part, by the Wellcome Trust (WT093205MA, WT104033AIA). This study makes use of data shared/provided through RDConnect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 (Solve-RD)., Armirola-Ricaurte C., Zonnekein N., Koutsis G., Amor-Barris S., Pelayo-Negro A.L., Atkinson D., Efthymiou S., Turchetti V., Dinopoulos A., Garcia A., Karakaya M., Moris G., Polat A.I., Yiş U., Espinos C., Van de Vondel L., De Vriendt E., Karadima G., Wirth B., Hanna M., Houlden H., Berciano J., Jordanova A.